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ABSTRACT: Alleviation of neuropathic pain by cannabinoids
is limited by their central nervous system (CNS) side effects.
Indole and indene compounds were engineered for high
hCB1R affinity, peripheral selectivity, metabolic stability, and
in vivo efficacy. An epithelial cell line assay identified
candidates with <1% blood−brain barrier penetration for
testing in a rat neuropathy induced by unilateral sciatic nerve
entrapment (SNE). The SNE-induced mechanical allodynia
was reversibly suppressed, partially or completely, after
intraperitoneal or oral administration of several indenes. At
doses that relieve neuropathy symptoms, the indenes
completely lacked, while the brain-permeant CB1R agonist
HU-210 (1) exhibited strong CNS side effects, in catalepsy, hypothermia, and motor incoordination assays. Pharmacokinetic
findings of ∼0.001 cerebrospinal fluid:plasma ratio further supported limited CNS penetration. Pretreatment with selective CB1R
or CB2R blockers suggested mainly CB1R contribution to an indene’s antiallodynic effects. Therefore, this class of CB1R
agonists holds promise as a viable treatment for neuropathic pain.
■ INTRODUCTION
Various neuropathies and chronic inflammatory conditions pose
a major socioeconomic and clinical challenge1 in part because of
poorly understood etiologies and mechanisms and in part
because side effects of existing treatments greatly limit their
effectiveness.2 This includes synthetic and naturally occurring
cannabinoids (CBs), which reduce the hyperalgesia and
allodynia associated with persistent pain of neuropathic and
inflammatory origin in humans3 and animals4 yet they exhibit
side effects mediated primarily by activation of central nervous
system (CNS) CB1 receptors (CB1Rs). These psychotropic
CNS effects also account for the abuse potential of plant-based
and synthetic CBs.
In addition to their CNS expression, CB1Rs, CB2Rs, and their
endogenous ligands (endocannabinoids, ECBs) have a diverse
distribution in peripheral tissues, including primary afferent
neurons.5 Local administration of CBs into inflamed tissue
attenuates hyperalgesia and allodynia via peripheral CBRs at
doses that produce minimal CNS-mediated side effects.6 The
crucial role of peripheral CBRs in the antihyperalgesic actions of
systemically administered CBs was demonstrated using condi-
tional deletion of CB1Rs located on nociceptive primary afferent
neurons.7 Also, many studies have demonstrated increases in
expression of CB1Rs, CB2Rs, and ECBs, both in the peripheral
tissues and the CNS, during inflammation and after development
of painful neuropathies, reviewed in ref 8. Increases in CBR
expression result in increased potency or efficacy of the
exogenously applied CBs9 and may also account for the
effectiveness of CBs in alleviating neuropathic pain symptoms
after chronic repeated treatment,10 unlike opioids, which have
only limited long-term effectiveness.11 While selective activation
of CB2Rs also inhibits experimentally induced inflammatory pain
and itch or the persistent pain of neuropathic origin,10b,12
activation of both CB1R and CB2Rs appears to have synergistic
effects on pain suppression.12a These studies provided a rationale
for the development of peripherally acting endocannabinoid-
based therapeutic interventions.13
With the aim of utilizing the demonstrated benefits of CBs to
sustainably ameliorate neuropathic pain, we sought to develop
peripherally restricted CB1R agonists, which would not
penetrate the blood−brain barrier (BBB) so as to avoid the
unwanted psychomimetic effects such as those caused by Δ9-
tetrahydrocannabinol (Δ9-THC) that are also associated with
activation of central CB1Rs. Peripheral restriction can be
addressed by (1) the inclusion of charge that typically prevents
BBB penetration in the absence of active transport, (2) the
presence of actively effluxed moieties such as carboxylates, and
(3) adjustment of partition coefficient and the topological polar
surface area. Other factors potentially impact peripheral
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restriction such as activation of CB2Rs on the BBB endothelial
cells.14 We chose to examine indoles and indenes that have been
demonstrated as ligands for CB1R agonist activity as starting
points for modifications toward these ends.
■ RESULTS
Synthesis of Indoles. The synthesis of the target indoles
where the 4-substituent of the naphthyl ring was alkyl or
hydrogen followed the established general approaches shown in
Scheme 1.15 The synthesis of indoles with a 4-acyl substituted
naphthylene ring required further modifications as described
below. The acylation of indole 1-1with the naphthoyl chloride 1-
2a (X1 = CO2Me) mediated by methyl magnesium bromide and
zinc chloride afforded the corresponding 1-3b in greater than
80% yield on scales of 20 g. Subsequent alkylation of 1-3bwith n-
pentyl bromide proceeded in yields of about 50% of 1-4a (X1 =
CO2Me) on a 1 g scale. Upon scale up to 10 and 15 g, the
alkylation step did not proceed to completion. Further, work up
resulted in hydroxysis or transesterification to the N-alkylated or
unalkylated acid or ethyl ester (when ethyl acetate was employed
in the work up) that can likely be addressed with modified work
up conditions.
Conversion of 1-4a to other 4-substituted naphthoyl indoles
was achieved by saponification to the acid 1-7a (X2 = CO2H, R =
Pn), which was converted to the acid chloride (X2 = COCl, R =
Pn) with oxalyl chloride and subsequently to the secondary
amide 1-7b (X2 = CONHMe, R = Pn) (87%) with methylamine
and to the primary amide 1-7c (X2 = CONH2) (98%) with
ammonium hydroxide. Conversion of the acid chloride to the
methyl or ethyl ketones 1-7e,d (X2 = COMe, COEt) by
treatment with either methyl Grignard (no product), dimethyl
zinc (trace product), diethyl zinc (trace product), or triethyl
aluminum (no product) was disappointing.
An alternative sequence to 1-7e,d of first preparing the 4-
substituted 1-naphthoyl chloride 1-2c,d (X1 = COMe, COEt)
followed by coupling to the indole (N-alkylated or not) was
examined in an effort to improve yields. Thus, commercially
available 4-(methoxycarbonyl)naphthalene-1-carboxylic acid (1-
8a) was converted to 1-2a (X1 = CO2Me), then treated with
dimethyl or diethyl zinc to afford 1-8b,c (X1 = COEt, COMe) in
63% and 37%, respectively, followed by hydrolysis of the esters to
the acids 1-8d,e in greater than 90% yield and treatment with
oxalyl chloride to afford 1-2c,d in near quantitative yield.
Acylating indole 1-1 with 1-2d (X1 = COEt) mediated with
MeMgBr afforded a 55% yield of 1-3d (X1 = COEt). Alkylation
of 1-3d with n-pentyl bromide, however, afforded no target
compound (the product obtained from the low yield diethyl zinc
reaction above was used for testing). Attempting synthesis of the
methyl ketone analogue 1-7e (X2 = COMe) by reversing the
sequence to acylating the prealkylated 1-6a (R = Pn) with 1-2c
(X1 = COMe) mediated by ethylaluminum dichloride gave a
complex mixture with minimal 1−7e (X2 = COMe) that could
not be isolated in pure form.
N-ω-Carboxyalkyl-indoles (butanoates and pentanoates, 1-4f
and 1-4g, respectively) were prepared by acylation of indole 1-1a
with 1-2e mediated by methylmagnesium bromide affording the
naphthoylindole 1-3a, which was then alkylated with ethyl ω-
bromoalkanoate and sodium hydride to yield the corresponding
ethyl butanoate and pentanoate and followed by hydrolysis to
provide the corresponding acids 1-4f,g (R = −(CH2)n-CO2H, n
= 3,4).16
Fluoroindole analogues were prepared from commercially
available fluoroindole substituted in the 4, 5, 6, or 7-position (1-
1b−e, Z = F) via acylation with 1-2e (X1 = H) in the presence of
MeMgBr and ZnCl2 to afford 1-3e−h in 70−85% yields followed
by alkylation with n-pentyl bromide/NaH to give 1-4h−k (Z =
F) in >80% yields. The 4-fluoro indole 1-3e was also alkylated
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with 5-fluoro-1-bromopentane/NaH to give the corresponding
1-4l in 27% yield. Similar alkylation with iodoethylmorpholine/
NaH afforded 1-4m (X1 = H, Z = 4-F, R = morpholinoethyl) in
68% yield after chloroethylmorpholine did not alkylate 1-3e (Z =
4-F). The analogue 1-4n (X1 = n-propyl, Z = 4-F, R = 5-F-pentyl)
was prepared from 4-fluoroindole 1-1b by acylation with 4-n-
propyl-1-naphthoyl chloride (1-2b, X1 = n-propyl) (MeMgBr,
ZnCl2) (58%), followed by alkylation with 5-fluoro-1-bromo-
pentane/NaH to give the corresponding 1-4n in 24% yield.
Synthesis of Indenes. Synthesis of the target 4-substituted
naphthylidene- or substituted benzylidene-3-morpholinoethyl-2-
indenes (2-5) with the E-olefin geometry was achieved as shown
in Scheme 2 by alkylation of lithiated indene 2-1with 1-chloro-2-
(4-morpholino)ethane (2-2) to afford a mixture of the 1- and 3-
alkylated 1H-indenes. Treatment of the mixture with sodium
hydroxide induced isomerization to the more stable 3-(4-
morpholinoethane)-1H-indene17 (2-3) in 45% yield (Z = H).
Treatment of 2-3 with the appropriate 1-naphthaldehyde,
benzaldehyde, or aryl aldehyde in the presence of sodium
methoxide gave the target E-olefin 2-5a−s after either 18 h of
heating at reflux (in 66% yield 2-5a) or microwave heating.
Microwave heating provided the same product more expedi-
tiously in 15 min at 105 °C but in lesser yield (53% 2-5a), a
process that we employed for themajority of the analogues which
were obtained in >90% purity (HPLC). Phenyl acetaldehyde, 4-
hydroxy-1-naphthaldehyde, 2-nitro-, and 2-cyano-benzaldehyde
were not ammenable to this method of synthesis, but particular
interest in preparing and testing the phenyl acetaldehyde derived
product, (1E)-3-hexyl-1-(2-phenylethylidene)-1H-indene (2-7)
with only a distal aromatic ring (see above), was achieved by
Horner−Wittig chemistry.17 The E-geometry was established for
the 2-5a−s analogues by comparison of the 1H NMR on the
architype E-(1-naphthylidene)-3-morpholinoethyl-2-indenes
prepared via the condensation chemistry from 2-3 with that
prepared by Horner−Wittig chemistry that was characterized by
NOE NMR spectroscopy.17
Neuropathy Testing. We examined the effectiveness of
select indenes in alleviating the painful symptoms of neuropathy
induced by unilateral sciatic nerve entrapment (SNE).18 SNE
was demonstrated to produce consistent pain behaviors,18,19 a
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transient loss of varicosities in nociceptive fibers,20 and increased
excitability of sciatic nerve.21 The hyperexcitability and ectopic
burst discharge of primary sensory neurons are widely
considered as major contributors to pain symptomatology of
peripheral neuropathy models. The SNE-induced mechanical
allodynia models the most common complaint of human
neuropathy patients of dynamic mechanical allodynia. Figure 1
illustrates that systemic injection of 0.3 mg/kg of PrNMI (2-5u)
or MoNMI (2-5j) results in large, reversible decreases in
mechanical allodynia. By contrast, ENMI (2-5a) has a much
smaller effect, consistent with its lower CBR affinity and faster
metabolism (Table 2).
Pharmacokinetics. Analysis of plasma samples after 2-5u
injections yielded its initial pharmacokinetic profile (Figure 1E),
which was in good agreement with its antiallodynic effects
(Figure 1B). Measurements of drug brain penetration include
drug partitioned into brain lipids + unbound drug in equilibrium
with extracellular fluid. The cerebrospinal fluid (CSF)/plasma
ratios are considered to be more precise estimates of a drug’s
brain penetration because of the continuity of CSF with
extracellular space.22 However, both measures are needed to
confirm minimal CNS access and to compare with other
reported peripherally restricted CB1R ligands.13c,23 Analysis of
plasma, brain, and CSF samples confirmed the minimal
penetration of 2-5u into the CNS after systemic administration
(Figure 1E).
In subsequent experiments, we demonstrated that 2-5u was
also effective in suppressing neuropathy symptoms after oral
administration, which is more representative of future
therapeutic uses. The high oral dose of 2-5u (3 mg/kg) likely
accounts for its continued antiallodynic effectiveness at the 24 h
time point (Figure 1F).
Tetrad Testing. The CNS-mediated psychotropic actions of
CB1R ligands represent their most troubling side effects. The
catalepsy, motor performance, hypothermia, and analgesia tests
are classically predictive of CNS CB1R activation.24 Effects in all
Figure 1. Reversible suppression of SNE-induced mechanical allodynia by representative indenes. (A) Schematic of sciatic nerve entrapment and
relevant peripheral nerve and spinal ganglia. (B) Graph of withdrawal thresholds to mechanical stimulation of hindpaws ipsilateral and contralateral to
SNE at 1 h before and 3, 6, 24, and 48 h after 2-5u (0.3 mg/kg, ip) injection. At 3 h postinjection, ipsilateral thresholds are increased to levels of predrug
contralateral thresholds and are indistinguishable from thresholds measured prior to neuropathy development (pre-SNE). Also note the drug-induced
small, but significant increases in contralateral thresholds (mean ± SEM, n = 8 rats). (C) In the same rats, administration of 2-5j (0.3 mg/kg), but not
vehicle alone, results in similar increases in ipsilateral thresholds to pre-SNE values. (D) 2-5a (0.3 mg/kg) produces considerably smaller increases in
thresholds than 2-5u or 2-5j. (E) Changes in plasma [2-5u] and calculated pharmacokinetic parameters after injection (0.3 mg/kg, ip) in naıv̈e rats (n =
3) are consistent with the time course of its effects on SNE neuropathy symptoms. Brain and CSF/plasma ratios of PrNMI obtained from samples
collected from 3 other rats at ∼75 min after 2-5u (0.3 mg/kg, ip) suggest minimal CNS penetration. (F) Oral administration of 2-5u (3 mg/kg)
reversibly suppresses SNE neuropathy symptoms (n = 8 rats). *, p < 0.05 vs predrug (−1 h) values (one-way RM ANOVA).
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four tests have been thought to be mediated by the activation of
central CB1Rs, but it is now well established that peripheral
CBRs make a major contribution to the analgesic effects of
CBs.6d,12a,c We used the “tetrad” to determine whether the novel
ligands have antinociceptive effects and side effect profile
consistent with central CB1R activation. We also studied the
potent CB1R agonist, 1 (HU-210, Scheme 3)25 (Tocris
Bioscience, Ellisville, MO), to allow comparisons of this positive
control with the putatively brain-impermeant analogues. The
systemic doses of 14b and of novel indenes (e.g., Figure 1) were
consistent with their demonstrated effectiveness in alleviating
painful neuropathy symptoms. The “tetrad” tests were modified
for rats, with rotarod substituting for the spontaneous activity
test. Unlike 1, 2-5u and other indenes lack effects in the catalepsy,
rotarod, or hypothermia assays, although a small effect in the tail-
flick assay is observed, as expected for analgesic peripherally
acting CB1R ligands (Figure 2).
CB1Rs Mediate Antiallodynic Effects of 2-5u. Despite
similar affinities for the CB1R and CB2R subtypes, indene
PRCBs are full agonists at hCB1R but only partial agonists at
hCB2R (Table 2). To determine which receptor subtype is
responsible for the antiallodynic effects of the novel CBR ligands
in the SNE neuropathy, we measured the ability of a
representative ligand, 2-5u, to suppress mechanical allodynia in
SNE rats in the presence of either CB1R or CB2R selective
antagonists. 2-5u was administered alone or 30 min after
pretreatment with CBR blockers in SNE rats at 3-day intervals
(Figure 3A). Pretreatment with the CB1R inverse agonist,
SR141716 (2, Scheme 3),26 completely blocked the antiallodynic
effect of 2-5u (Figure 3B,E), whereas pretreatment with a CB2R
selective inverse agonist, SR144528 (3, Scheme 3), had little
effect on suppression of allodynia by 2-5u (Figure 3D). In the
same rats, pretreatment with a peripherally restricted analogue of
2, 18A, recently developed by our group,27 also prevented the
antiallodynic effect of 2-5u (Figure 3C,E). These studies
demonstrated the CB1R dependence of 2-5u’s antiallodynic
effects in the SNE neuropathy.
■ DISCUSSION
Structure−Activity Relationships (SAR). The introduc-
tion of charge to CB1R ligands to impart peripheral selectivity
was explored via quaternization of morpholinoethyl-indoles and
-indenes of demonstrated CB1R agonists. Thus, morpholinoe-
thylindoles 1-[2-(4-morpholino)ethyl]-3-(1-naphthoyl)indole
(1-9a, JWH-200),15a 1-[2-(4-morpholino)ethyl]-3-(4-methoxy-
1-naphthoyl)indole (1-9c, JWH-198),15a and 1-[2-(4-
morpholino)ethyl]-3-(4-methyl-1-naphthoyl)indole (1-9e,
JWH-193),15a respectively, and pravadoline28 1-9g were
quaternized to 1-9b,d,f,h. Also, conformationally constrained
morpholinoethyl indenes, (2-5a, E-4-[2-[1-(1-naphthalenyl-
methylene)-1H-inden-3-yl]ethyl]morpholine)17 and its 2-meth-
yl analogue 2-5v, were quaternized to afford the corresponding
charged quaternary ammonium analogues (2-6a and 2-6b). Both
of these changes resulted in a reduction of hCB1R binding
affinity of between one and 2 orders of magnitude (see Table 1).
Similarly, alkyl carboxy chains linked to the indole nitrogen asω-
butanoic (1-4f) and -pentanoic (1-4g) acids, as putative effluxed
moieties, also exhibited no hCB1R affinity (Ki = > 10 μM) in
contrast to the unmodified pentyl chain of 3-(naphthalene-1-
carbonyl)-1-pentyl-1H-indole, JWH-018 (1-4p) (Ki = 4.3
nM).15a The 4-carboxy substituted naphthoyl analogue 1-7a
also showed no receptor affinity (Ki = >10 μM). These results
steered our efforts away from charged analogues.
Screening results of peripheral selectivity and hCB1R affinity
on our early analogues redirected ligand design. The peripheral
selectivity of the high affinity compounds was tested in the
Madin−Darby canine kidney (MDCK) epithelial cell line assay
as a model of the BBB29 and showed an association with the n-
pentyl indoles and morpholinoethyl indenes, respectively. Thus,
the N-pentyl 4-carboxy methyl ester indole 1-4a was compared
to the N-morpholinoethyl 4-carboxy methyl ester indole
analogue 1-4o. The basolateral:apical ratio (B:A) of the n-pentyl
analogue 1-4a was 0.00, while that of the N-morpholinoethyl
analogue 1-4o was 1.02, indicating nonpermeability of 1-4a and
equal central:peripheral distribution of 1-4o in the MDCK
model. This would suggest similar permeability for these indole
analogues across the BBB.
The morpholinoethyl indene 2-5a17 and the n-pentyl indene
1-{[(1E)-3-pentyl-1H-inden-1-ylidene]methyl}naphthalene,
JWH-176,15a 2-7a, were also chosen as candidates for
modification as they had high affinity for the CB1R (Ki = 4.69
and 17.2 nM, respectively). Surprisingly, both tested in the
MDCK assay29 as peripherally restricted (B:A = 0.00 and 0.04,
respectively) with the morpholinoethyl moiety 2-5a, showing
slightly greater preferral restriction over the pentyl moiety (2-
7a). This is the opposite order of the indole morpholinoethyl and
the indole pentyl side chain pair tested (above) and of significant
difference of B:A of the morpholinoethyl substituted indole 1-4o.
Thus, subsequent indene modifications were evolved from the
morpholinoethyl indene analogue 2-5a and subsequent indole
modifications were evolved from n-pentyl indoles to examine
SAR trends in affinity, MDCK permeability, and metabolic
stability in order to select candidates for in vivo testing.
The effect upon hCB1R affinity of substituting the naphthoyl
4-position on the indoles, which has been associated with high
receptor affinity in reported analogues,15b was examined in the
N-pentyl family. Thus, in contrast to the 4-carboxy substituted
naphthoyl analogue 1-7a (Ki = >10 μM), the corresponding ethyl
Scheme 3
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ester (1-4c) exhibited aKi = 115 nM and the shorter methyl ester
(1-4a) exhibited a Ki = 20 nM. The three atom-long chain 4-
propanoyl-naphthyl analogue (1-7d) exhibited a Ki = 5.7 nM.
The 4-N-methylamido analogue 1-7b (Ki = 127 nM) was less
active than its isosteric oxygen or carbon analogues (1-4a and 1-
7d). The 4-amido analogue (1-7c), however, had higher affinity
for hCB1R (Ki = 96 nM) than the corresponding acid 1-7a.
A similar effect of the 4-position substituent was observed for
the indenes in the morpholinoethyl family. The hCB1R affinity
progressed from 4-H (4.69 nM) (2-5a) to 4-OMe (2.43 nM) (2-
5j) to 4-n-Pr (1.18 nM) (2-5u) to 4-Et (0.86 nM) (2-5t), all of
which were subsequently tested in vivo.
Modeling and SAR studies of indole CB1R agonists and,
similarly for the indene mimics of the indoles, support that the
Figure 2. Activity of 1, 2-5u, 2-5t, and 2-5j in the “tetrad” assays. (A−D) Rats were tested in each assay 1 h prior and up to 48 h following intraperitoneal
injection of vehicle, 1 (0.01 mg/kg) or 2-5u (0.3 mg/kg). Note the profound CNS side effects of 1 vs 2-5u in the ring, core temperature, and rotarod
tests. The small analgesic effect of 2-5u in the tail-flick assay is consistent with peripheral activation of CBRs. *, p < 0.05 vs predrug (−1 h) values (one-
way RM ANOVA). (E−H) Dose-dependence of brain-permeant 1 and compounds 2-5t, 2-5u, or 2-5j in the tetrad assays after intraperitoneal
administration. Each point represents mean peak effect± SEM of 1 (n = 6 rats), 2-5t (n = 8 rats), 2-5u (n = 8 rats), and 2-5j (n = 8 rats), each subtracted
from its vehicle control. (I−L) Dose-dependence of 2-5t, 2-5u, and 2-5j in the tetrad assays after oral administration. Each point represents mean peak
effect± SEM of 2-5t (n = 8 rats), 2-5u (n = 8 rats), and 2-5j (n = 8 rats), each subtracted from its vehicle control. Note the relative lack of side effects in
the catalepsy, motor incoordination, and hypothermia assays. The small effects in the tail-flick assay are consistent with antinociceptive effects due to
activation of peripheral CBRs in naıv̈e rats.
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favored conformation of the naphthoyl ring for binding/
activation in the analogues of 1-4p and 5 (WIN 55,212-2)28 in
the CB1R site is one in which the naphthoyl ring is nearly parallel
to the XZ plane when the indole ring (pentyl chain pointing
down) is in the XY plane.15a,17,30 Further, for the indoles, it is the
distal ring of the naphthoyl bicyclic system that has the role of
binding stabilization by aromatic stacking interactions with the
receptor pocket.31 Hence, we prepared and tested the 2-
phenylethylidene indene analogue (2-7c) wherein the naph-
thylidene ring was replaced with 2-phenylethylidene that retains
only the distal aromatic ring in analogy with similar active indole
analogues.32 This change lost 10-fold affinity versus the
corresponding naphthylidene analogue 2-7b (both with an n-
hexyl pendant group on inden-3-yl) and 256-fold versus 2-7a,
which carries a pentyl pendant group on inden-3-yl).
Reported studies on indenes that are conformationally
restrained by an arylidene double bond indicate that it is the
orientation defined by the E-geometry that is active in the
indenes and, by extension, in the more conformationally mobile
naphthoyl indoles.17 Designing forward from these factors, other
arrangements of arylidene rings on the indenes were synthesized
and tested to evolve an SAR that mapped the regions proximal to
the 1-naphthyl ring. Thus, fusing an additional phenyl ring to
naphthylene gave the 5-phenanthrylidene ring (2-5s) (Ki = 22.9
nM) versus the naphylidene 2-5a (4.69 nM), indicating a
tolerence for the extra ligand volume. In contrast, an alternate
fusing of a phenyl ring to a naphthyl ring in indoles to give the
symmetrical 9-anthranoyl ring is reported to result in a significant
loss of binding affinity.31 This suggests that the volume available
to the naphthoyl is not equivalent on both sides of the 9-
anthranoyl bond to the indole and by extension to the indene.
Displacing the distal phenyl ring of the naphthylidene group of
2-5a from the fused to a pendant arrangement as in a 2- or 3-
phenylbenzylidene group (2-5k and 2-5e, respectively) results in
a reasonably tolerated receptor binding for hCB1R for 2-5k (Ki =
82.9 nM) but not for 2-5e (Ki = 2603 nM). Reorienting the 1-
naphylidene ring to the 2-naphylidene ring (2-5r) (Ki = 134 nM)
reduces binding affinity by a moderate extent.
Ortho-substituted benzylidene morpholinoethyl indenes were
also synthesized and screened for hCB1R affinity based on the
reported activity of 2-substituted benzoyl indoles.15b Versus the
unsubstituted 2-protio analogue 2-5b (Ki = 1297 nM), the 2-
halogeno analogues (2-5d,f,g,c) (2-F, Cl, Br, I, respectively)
showed increasing affinity (Ki = 1000, 862, 647, 607 nM,
respectively) with larger halogen atoms but never rising to the
effect of the much larger 2-phenylbenzylidene analogue (2-5k, Ki
= 82.9 nM). The 2-methoxy substituent (2-5h, Ki = 149 nM)
gave a large increase in binding affinity (vs 2-5b) that was likely
due to electronic issues given the similar enhancement in affinity
seen for the 4-methoxynaphthylidene 2-5j vs 2-5a.
The affinity and possibly the functional bias of the receptor
with its binding ligand can be influenced by the interaction of the
arylidene or aroyl moieties of the indenes or the indoles,
respectively. Modeling suggests that this interaction is one of
aromatic stacking, which is effected by the electronic character of
the interacting aromatic rings. Varying the arylidene ring systems
to introduce electron-rich and electron-poor proximal or distal
rings, we examined the effect on binding affinity. Thus,
comparing the monocyclic electron-rich furanylidene 2-5n (Ki
Figure 3.CB1Rs mediate antiallodynic effects of 2-5u in the SNE neuropathy. (A) Suppression of SNE-induced mechanical allodynia by 2-5u (0.6 mg/
kg). (B) In the same rats (n = 8), pretreatment with the CB1R inhibitor 2 (rimonabant, 3 mg/kg, ip) completely blocks the response to 2-5u. (C) A
peripherally restricted rimonabant analogue, 18A, also blocked the response to 2-5u. (D) By contrast, the selective CB2R inhibitor 3 (3 mg/kg, ip)
produced only a small decrease in the response to 2-5u. (E) Summary of effects of selective CB1R and CB2R inhibition on antiallodynic effects of 2-5u.
*, p < 0.05 vs treatment with 2-5u alone (one-way ANOVA).
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Table 1. Compounds Key: Indoles (1) and Indenes (2)
compd Z R X1/2
a Ki (nM) hCB1R vs CP55,940
1-4a H Pn CO2Me 20.2
1-4b H H CO2Et
1-4c H Pn CO2Et 115
1-4d H (CH2)3-CO2Et H 747
1-4e H (CH2)4-CO2Et H 1469
1-4f H (CH2)3-CO2H H >10000
1-4g H (CH2)4-CO2H H >10000
1-4h 4-F Pn H 6.5
1-4i 5-F Pn H 9.85
1-4j 6-F Pn H 2.35
1-4k 7-F Pn H 3.62
1-4l 4-F 5-F-Pn H 4.38
1-4m 4-F Et-Morp H 237
1-4n 4-F 5-F-Pn 4-Pr 2.55
1-4o H Et-Morp CO2Me 52.4
1-4p H Pn H 4.3 (15a)
1-7a H Pn CO2H >10000
1-7b H Pn CONHMe 127
1-7c H Pn CONH2 96.6
1-7d H Pn COEt 5.71
1-7e H Pn, not prep COMe not tested
1-9a H Et-Morp H 82
1-9b H Me, Et-Morp H >10000
1-9c H Et-Morp OMe 88
1-9d H Me, Et-Morp OMe 4083
1-9e H Et-Morp Me 20
1-9f H Me, Et-Morp Me 4174
1-9g Et-Morp pravadoline 2511 (rat)
1-9h Me, Et-Morp Me-pravadoline >10000
compd R E-arylidene (morpholinoethyl indene) W/X1 Ki (nM) hCB1R vs CP55,940
2-5a ENMI Et-Morp 1-naphthylidene H 4.69 (2.72)
2-5b Et-Morp benzylidene H 1297
2-5c Et-Morp 2-iodobenzylidene 2-I 607
2-5d Et-Morp 2-fluorobenzylidene 2-F 1000
2-5e Et-Morp 3-phenylbenzylidene 3-Ph 2603
2-5f Et-Morp 2-chlorobenzylidene 2-Cl 862
2-5g Et-Morp 2-bromobenzylidene 2-Br 647
2-5h Et-Morp 2-methoxybenzylidene 2-OMe 149
2-5i Et-Morp 2-methylbenzylidene 2-Me 623
2-5j MoNMI Et-Morp 4-methoxynaphthylidene 4-OMe 2.43
2-5k Et-Morp 2-phenylbenzylidene 2-Ph 82.9
2-5l Et-Morp 7-indolidene H 107
2-5m Et-Morp 2-thienylmethylene H 8528
2-5n Et-Morp 2-furanylmethylene H >10000
2-5o Et-Morp 5-isoquinolidene H 454
2-5p Et-Morp 4-quinolidene H 23.3
2-5q AceNMI Et-Morp 1,2-dihydroacenaphthylidene-5-yl-methylene 15.9
2-5r Et-Morp 2-naphthylidene 134
2-5s Et-Morp 4-phenanthrylidene 22.9
2-5t EtNMI Et-Morp 4-ethylnaphthylidene Et 0.859
2-5u PrNMI Et-Morp 4-propylnaphthylidene Pr 1.18
2-5v Et-Morp 1-naphthylidene (2-Me-indene) H 2.84 (2.89)
2-6a Me, Et-Morp 1-naphthylidene (indene) 982
2-6b Me, Et-Morp 1-naphthylidene (2-Me-indene) 1614
2-7a Pn 1-naphthylidene (indene) 17.2 (26)
2-7b Hx 1-naphthylidene (indene) 436
2-7c Hx E-2-phenylethylidene 4414
aSee Schemes 1 and 2 for X1 and X2
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= > 10 μM) to the electron-poor thiophenylidene 2-5m (Ki = 8.5
μM), binding is favored by the electron-poor proximal ring.
Similarly, comparing the bicyclic electron-poor 4-quinolidene 2-
5p (Ki = 23.3 nM) to the electron-neutral naphthylidene 2-5a (Ki
= 4.69 nM), binding is favored by the electron-neutral (or
relatively electron-rich) proximal ring. Even though the binding
by the electron-poor proximal ring was quite good, other factors
such as interaction with the basic nitrogen atoms could
contribute to the overall binding preference change toward
electron density. Comparing the bicyclic electron-rich 7-
indolydene 2-5l (Ki = 107 nM) to the electron-poor 5-
isoquinolidene 2-5o (Ki = 454 nM), binding is favored by the
electron-rich distal ring.
Given the ready metabolism of indoles, which not only leads to
the consumption of the drug candidate but also to multiple
metabolites that exhibit mixed pharmacologies,33 the issue of
stabilizing lead compounds was also addressed by introducing
fluorine substitution on the indole ring to develop improved
resistance to metabolism. The 4-, 5-, 6-, and 7-F indole analogues
of 1-4p (1-4h−k) all had Kis in the single-digit nM range. Tested
for stability in rat plasma, where they exhibited stability of 69−
99% after 1 h (see Table 3), and S9 plasma fraction, where
stability increased from 3% to 50% in 1 h with F substitution
going from positions 4 to 7. In our analogues, the indenes were
more metabolically stable than the indoles.
In Vivo Efficacy of Indenes. We show that systemic (0.3
mg/kg, ip) administration of 2-5u (2-5u) or 2-5j (2-5j)
produced complete suppression of mechanical allodynia
symptoms (Figure 1B,C), while the same and 3-fold higher
doses of these compounds had no effect in the assays of CNS
CB1R activation compared to the brain-permeant positive
control, 1 (Figure 2). Similarly, an oral dose of 3 mg/kg 2-5u
produced complete suppression of allodynia symptoms at peak
effect, while a 10 mg/kg oral dose had no significant effect on
central CB1Rs (Figure 2). These data support the high
antiallodynic efficacy of indene-based peripherally restricted
cannabinoids (PRCBs) at doses that do not produce any CNS
side effects.
Table 2. E-Arylidene Morpholinoethyl Indene Structures, hCB1R/hCB2R Binding, Permeability in the MDCK Cell Line Assay,
Ca2+ Flux (hCB1R and hCB2R Agonist) Activity, and Metabolic Stabilitya
a--, not tested.
Table 3. Indole Core Structures, hCB1R/hCB2R Binding, Permeability in the MDCKCell Line Assay, Ca2+ Flux (hCB1R agonist)
Activity, and Metabolic Stabilitya
a-- not tested.
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The pharmacokinetic data, which showed a CSF:plasma ratio
of 0.001 at ∼75 min after 2-5u (0.3 mg/kg, ip) administration
(Figure 1E) supports its relative lack of brain permeability.
Generally, increasing aqueous solubility decreases the likelihood
of a drug gaining access to brain tissue. However, numerous lipid-
soluble molecules, among them many useful therapeutic drugs,
have lower brain permeability than would be predicted from a
determination of their lipid solubility.34 Given the very low
aqueous solubility of PRCBs, their relative lack of BBB
permeability suggests that they may be substrates for active
drug efflux transporters such as P-glycoprotein or multidrug
resistance proteins. Future studies using selective inhibitors of
such transporters (e.g., ref 35) or transporter knockout rodents
(e.g., ref 36) should help identify precisely the efflux transporters
for which PRCBs serve as substrates.
We also demonstrated that PRCBs such as 2-5u have small
effects on acute nociception compared to the brain-permeable 1
in the tail-flick assay in naıv̈e rats (Figure 2D,H,L), yet at the
same doses exhibit potent antiallodynic effects in SNE
neuropathy. Previous studies have demonstrated increases in
expression of both CB1R and CB2R in sensory ganglia after
inflammation and peripheral nerve injuries.6a,37 Increases in CBR
expression result in increased potency or efficacy of the
exogenously applied CBs;9 such increases may also account for
the effectiveness of CBs in alleviating neuropathic pain
symptoms after chronic repeated treatment.10 Thus, increases
in CB1R and CB2R expression may potentially account for the
increased potency/efficacy of PRCBs after SNE injury. An
alternative explanation for the increased efficacy of 2-5u in SNE
involves alterations in blood−nerve barrier (BNB) function.
Many of the BBB efflux transporters are also involved in
maintaining BNB function.38 In normal conditions, these
transporters may limit PRCB access to CBRs on nociceptors,
which would account for the weak antinociceptive efficacy of
PRCBs. However, there is growing evidence that chronic pain
syndromes exhibit tissue abnormalities caused by micro-
vasculature dysfunction in the blood vessels of skin, muscle, or
nerve.39 Such dysfunction, e.g., loosening of the tight junctions
between the endoneurial endothelial cells,38 may increase PRCB
access to CBRs on sensory neurons, thereby increasing their
effectiveness in suppressing painful neuropathy symptoms.
Our binding studies revealed similar affinities of 2-5u and
related indenes for the CB1R and CB2R subtypes. However,
subsequent Ca2+ flux assays revealed that indene PRCBs are full
agonists at hCB1R but only partial agonists at hCB2R (Table 2).
In vivo, pretreatment with the CB2R-selective inverse agonist, 3
(Scheme 3), had only a small effect on suppression of allodynia
by 2-5u, while pretreatment with the brain-permeable CB1R-
selective inverse agonist, rimonabant, or it is peripherally
restricted analogue, 18A,27 prevented the antiallodynic effect of
2-5u (Figure 3). These studies suggested that CB1Rs are mainly
responsible for the antiallodynic effects of PRCBs. Previous
studies with the brain-permeant synthetic CB, 4 (Scheme 3),
which has full agonist activity at both CB1R and CB2R,
demonstrated that its antiallodynic effects in some neuropathy
models were mediated primarily by CB1R activation,6c,10a,40
whereas in other models both CB1R and CB2R were
involved.12d,41 Further, our conclusions must be tempered by
the fact that in vivo effects of inverse agonists such as rimonabant
may be affected by changes in levels of endocannabinoids and
their activation of CBRs in SNE neuropathy. Future studies using
transgenic mice with deletions of CB1Rs and CB2Rs should be
able to determine more precisely the relative contribution of
CBR subtypes to the antiallodynic effects of PRCBs in different
neuropathy models.
■ CONCLUSIONS
The hydrophobic PRCB compounds, which we developed, are
the first in their class of high peripheral selectivity CB1R agonists
to exhibit, after systemic or oral administration, potent, and
repeated suppression of neuropathy symptoms with a lack of side
effects mediated by activation of central CB1 receptors. The
potency, peripheral selectivity, in vivo efficacy, and absence of
CNS side effects of the PRCBs hold promise as a viable treatment
for neuropathic pain states.
■ EXPERIMENTAL METHODS
General. 1H and 13C NMR spectra were run on a Bruker Avance 300
MHz or a Varian Unity Inova 500 MHz NMR spectrometer. Mass
spectra (MS) were run on a PerkinElmer Sciex API 150 EX mass
spectrometer. High resolution mass spectra (HRMS) were run on a
Waters Synapt G2 Q-TOF mass spectrometer in high-resolution mode.
Column chromatography was carried out using a Teledyne Isco
Combiflash Rf system with RediSep Rf silica cartridges. Preparative thin
layer chromatography was carried out using Analtech TLC Uniplates
(silica gel, 1000 mm, 20 cm × 20 cm). High pressure liquid
chromatography was performed using a system consisting of a Waters
1525 pump unit, driven by Empower software, and a Waters 2487
detector. Microwave chemistry was carried out using a CEM Discover
SP microwave with 10 mL irradiation tubes.
4-Propylnaphthalene-1-carbonyl Chloride (1-2b). 4-Propylnaph-
thalene-1-carboxylic acid (500 mg, 2.33 mmol) was dissolved in
dichloromethane (15 mL) and cooled to 0 °C in an ice bath. Oxalyl
chloride (1.49 g) was then added dropwise over 5 min. Once the
addition was complete, the mixture was allowed to stir at room
temperature for 45 min and then under reflux for 45 min. The solution
was then cooled to room temperature. Removal of the solvent afforded
4-propylnaphthalene-1-carbonyl chloride (1-2b), which was used in the
preparation of 1-3f without further purification (assuming 542 mg,
100%).
Methyl 4-[(1H-Indol-3-yl)carbonyl]naphthalene-1-carboxylate (1-
3b). Indole (1-1) (8.12 g, 98%, 0.068 mol) was dissolved in
dichloromethane (150 mL), purged with nitrogen, and cooled to 0 °C
in an ice bath. Methylmagnesium bromide (0.023 L, 3 M in ether, 0.069
mol) was added to the solution over 10 min and mixture stirred for an
additional 10 min at 0 °C. Powdered ZnCl2 (31.3 g, solid addition
funnel) and anhydrous ether (80 mL, addition funnel) were then added
over 10min and the mixture stirred for an additional 10 min at 0 °C. The
solution was allowed to warm to room temperature and stirred for 30
min. Methyl 4-(carbonochloridoyl)naphthalene-1-carboxylate (1-2a)
(17.24 g, 0.069 mol) in CH2CL2 (80 mL) was then added over several
minutes and the solution stirred at room temperature overnight.
Subsequently, saturated aqueous ammonium chloride solution (80 mL)
was added and the mixture stirred for 15 min. The solid was removed by
filtration and washed with water and ether. This solid was vacuumed
dried to give the title product (11.97 g). The organic and aqueous layers
of the filtrate were then separated. The organic layer was then washed
with water, dried over sodium sulfate, and the solvent removed under
reduced pressure. The residue was then triturated with a small amount of
ether. The solid was removed by filtration and vacuumed dried to give
additional product (8.36 g, 20.33 g total, 91%). 1H NMR (300 MHz,
CDCl3) δ 4.05 (s, 3H), 7.31−7.52 (m, 5H), 7.58−7.67 (m, 2H), 8.12 (d,
J = 8.4 Hz, 1H), 8.18 (d, J = 7.4 Hz, 1H), 8.45−8.52 (m, 1H), 8.78 (br s,
1H), 8.91 (d, J = 8.6 Hz, 1H).
X-Fluoro-3-[(naphthalen-1-yl)carbonyl]-1H-indole (X = 4−7) (1-
3e−h). These analogues were prepared by a similar method described
for 1−3b with variations of additional further extractions of the aqueous
layer with ether or dichloromethane, drying, and trituration in
dichloromethane or ether.
4-Fluoro-3-[(naphthalen-1-yl)carbonyl]-1H-indole (1-3e). 4-Fluo-
roindole (1-1b) (2.03 g, 0.0147 mol) was dissolved in dichloromethane
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(60 mL) and cooled to 0 °C in an ice bath. Methylmagnesium bromide
(0.005 L, 3 M in ether, 0.015 mol) was added to the solution, under
nitrogen, over 5 min. The mixture was then stirred for 10 min at 0 °C,
ZnCl2 solution (0.0049 L, 1 M in ether, 0.0496 mol) added dropwise
over 10 min, and the mixture stirred for an additional 10 min at 0 °C.
The solution was allowed to warm to room temperature and stir for 30
min. 1-Naphthoyl chloride (1-2e) (0.002 L, 97%, 0.015 mol) was then
added over several minutes and the solution stirred at room temperature
overnight. Subsequently, saturated aqueous ammonium chloride
solution (120 mL) was added and the mixture stirred for 30 min. The
precipitate was removed by filtration, washed well with water, and dried
under vacuum to give the title compound as an off-white solid (3.40 g,
80%). 1H NMR (300 MHz, DMSO-d6) δ 6.95−7.05 (m, 1H), 7.23−
7.33 (m, 1H), 7.38 (d, J = 8.0 Hz, 1C), 7.48−7.62 (m, 3H), 7.65−7.73
(m, 2H), 8.00−8.13 (m, 3H), 8.08−8.17 (m, 2H), 12.30 (s, 1H). 13C
NMR (75.5 MHz, DMSO-d6) δ 107.51 (d, J = 20.8 Hz, 1C), 108.82 (d, J
=J = 3.8 Hz, 1C), 113.37 (d, J = 21.2 Hz, 1C), 117.20 (d, J = 5.9 Hz, 1C),
124.15 (d, J = 7.5 Hz, 1C), 124.80, 125.28, 126.20 (2C), 126.75, 128.28,
129.91, 130.25, 133.25, 137.22, 138.81 (d, J = 2.3 Hz, 1C), 140.03 (d, J =
11.4 Hz, 1C), 155.88 (d, J = 251.0 Hz, 1C), 189.48.
5-Fluoro-3-[(naphthalen-1-yl)carbonyl]-1H-indole (1-3f). Off-
white solid (3.37 g, 85%). 1H NMR (300 MHz, DMSO-d6) δ 7.11−
7.22 (m, 1H), 7.48−7.67 (m, 4H), 7.68−7.75 (m, 1H), 7.78 (s, 1H),
7.94−8.14 (m, 4H), 12.20 (s, 1H). 13C NMR (75.5 MHz, DMSO-d6) δ
106.28 (d, J = 24.6 Hz, 1C), 111.39 (d, J = 26.0 Hz, 1C), 113.71 (d, J =
9.8 Hz, 1C), 117.17 (d, J = 4.4 Hz, 1C), 124.88, 125.22, 125.73, 126.25,
126.44 (d, J = 11.0 Hz, 1C), 126.74, 128.27, 129.78, 129.99,133.29,
133.56, 138.01, 138.23, 158.83 (d, J = 234.9 Hz, 1C), 191.17.
6-Fluoro-3-[(naphthalen-1-yl)carbonyl]-1H-indole (1-3g). Light-
pink solid (3.42 g total, 80%). 1H NMR (300 MHz, DMSO-d6) δ 7.11−
7.22 (m, 1H), 7.30−7.38 (m, 1H), 7.48−7.66 (m, 3H), 7.67−7.76 (m,
2H), 7.97−8.06 (m, 2H), 8.10 (d, J = 8.1 Hz, 1H), 8.25−8.36 (m, 1H),
12.12 (s, 1H). 13C NMR (75.5 MHz, DMSO-d6) δ 98.67 (d, J = 25.8 Hz,
1C), 110.44 (d, J = 23.9 Hz, 1C), 117.10, 122.52 (d, J = 1.7 Hz, 1C),
122.66, 124.86, 125.23, 125.75, 126.24, 126.74, 128.27, 129.76, 130.01,
133.28, 137.08 (d, J = 12.5 Hz, 1C), 137.35 (d, J = 1.9 Hz, 1C), 138.25,
159.46 (d, J = 237.4 Hz, 1C), 191.23.
7-Fluoro-3-[(naphthalen-1-yl)carbonyl]-1H-indole (1-3h). White
solid (1.51 g total, 72%). 1H NMR (300 MHz, DMSO-d6) δ 7.11−7.21
(m, 1H), 7.22−7.32 (m, 1H), 7.49−7.68 (m, 3H), 7.70−7.78 (m, 2H),
8.00−8.07 (m, 2H), 8.08−8.17 (m, 2H), 12.68 (s, 1H). 13C NMR (75.5
MHz, DMSO-d6) δ 108.30 (d, J = 15.8 Hz, 1C), 117.56 (d, J = 3.5 Hz,
1C), 117.91 (d, J = 1.3 Hz, 1C), 122.80 (d, J = 6.0 Hz, 1C), 124.76 (d, J =
13.3 Hz, 1C), 124.89, 125.19, 125.92, 126.26, 126.78, 128.30, 129.47 (d,
J = 4.6 Hz, 1C), 129.92, 129.99, 133.31, 137.06, 138.18, 149.12 (d, J =
245.1 Hz, 1C), 191.34.
4-Fluoro-3-[(4-propylnaphthalen-1-yl)carbonyl]-1H-indole (1-3i).
4-Fluoroindole (1-1b) (1.47 mmol), methylmagnesium bromide (2.4
mmol), ZnCl2 solution (1 M in ether, 8.0 mmol), and 4-
propylnaphthalene-1-carbonyl chloride32 (1-2b) (2.33 mmol) were
similarly processed as for 1-3b. White solid (440 mg total, 58%). 1H
NMR (300 MHz, DMSO-d6) δ 1.02 (t, J = 7.3 Hz, 3C), 1.67−1.82 (m,
2H), 3.09 (t, J = 7.4 Hz, 2C), 6.92−7.02 (m, 1H), 7.20−7.31 (m, 1H),
7.36 (d, J = 8.0 Hz, 1H), 7.42 (d, J = 7.2 Hz, 1H), 7.47−7.63 (m, 3H),
7.66 (s, 1H), 8.09 (d, J = 8.1 Hz, 1H), 8.17 (d, J = 8.3 Hz, 1H), 12.30 (s,
1H). 13C NMR (75.5 MHz, DMSO-d6) δ 13.99, 23.45, 34.47, 107.41 (d,
J = 20.8 Hz, 1C), 108.80 (d, J = 3.7 Hz, 1C), 113.44 (d, J = 21.1 Hz, 1C),
117.31 (d, J = 5.9 Hz, 1C), 124.03 (d, J = 7.7 Hz, 1C), 124.12, 124.73,
126.07 (3C), 126.22, 130.75, 131.58, 137.00, 137.28 (d, J = 2.4 Hz, 1C),
140.02 (d, J = 11.4 Hz, 1C), 140.60, 155.90 (d, J = 251.1 Hz, 1C),
189.63.
Methyl 4-[(1-Pentyl-1H-indol-3-yl)carbonyl]naphthalene-1-car-
boxylate (1-4a). DMF (15 mL) was cooled to 0 °C, and sodium
hydride (245 mg, 60% in mineral oil, 6.1 mmol) added over a few
minutes. After the addition was complete, the mixture was stirred for an
additional 10 min before adding a solution of methyl 4-[(1H-Indol-3-
yl)carbonyl]naphthalene-1-carboxylate (1-3b) (1 g, 0.003 mol) in DMF
(15 mL) dropwise. The solution was then stirred for 30 min at 0 °C. A
solution of pentyl bromide (0.415 mL) in DMF (8 mL) was added and
the mixture allowed to warm to room temperature and stirred overnight.
The solvent was removed under reduced pressure and EtOAc (25 mL)
and water (25 mL) added to the residue. The mixture was shaken and
the organic layer removed and washed with water. The solvent was
removed under reduced pressure and residue was columned over silica
gel (Isco, gradient from 100% hexane to 30% EtOAc/70% hexane) to
give the title product as an off-white solid (630 mg, 52%). 1HNMR (300
MHz, CDCl3) δ 0.84 (t, J = 6.6 Hz, 3H), 1.17−1.37 (m, 4H), 1.72−1.88
(m, 2H), 3.98−4.10 (m, 5H), 7.23−7.29 (m, 1H), 7.32−7.43 (m, 3H),
7.44−7.54 (m, 1H), 7.68−7.78 (m, 2H), 8.09−8.17 (m, 1H), 8.20 (d, J =
7.4 Hz, 1H), 8.42−8.50 (m, 1H), 8.92 (d, J = 8.5 Hz, 1H).
Ethyl 4-[(1H-Indol-3-yl)carbonyl]naphthalene-1-carboxylate (1-
4b) and Ethyl 4-[(1-Pentyl-1H-indol-3-yl)carbonyl]naphthalene-1-
carboxylate (1-4c). DMF (150 mL) was cooled to 0 °C and sodium
hydride (3.68 g, 60% in mineral oil, 0.092 mol) was added over several
minutes. The mixture was then stirred for an additional 10 min, and a
solution of methyl 4-[(1H-Indol-3-yl)carbonyl]naphthalene-1-carbox-
ylate (1-3b) (15 g, 0.046 mol) in DMF (150 mL) was added dropwise.
The solution was then stirred for 30 min at 0 °C. A solution of pentyl
bromide (7.56 g, 0.05 mol) in DMF (75 mL) was added and the mixture
allowed to warm to room temperature and stir overnight. The solvent
was removed, EtOAc (100 mL) added to the residue, and the inorganic
solid removed by filtration. Water (100 mL) was then added to the
filtrate and the mixture stirred for 10 min. The organic layer was
removed, dried over sodium sulfate, and the solvent removed under
reduced pressure. The residue was purified over silica gel (Isco, gradient
from 100% hexane to 30% EtOAc/70% hexane) to give the title
compounds via transesterification as light-yellow solids.
Ethyl 4-[(1H-Indol-3-yl)carbonyl]naphthalene-1-carboxylate (1-
4b). Yield (3.0 g, 19%). 1H NMR (300 MHz, CDCl3) δ 1.49 (t, J = 7.1
Hz, 3H), 4.52 (q, J = 7.1 Hz, 2H), 7.26 (s, 1H), 7.28−7.49 (m, 4H),
7.54−7.65 (m, 2H), 8.09 (d, J = 8.5 Hz, 1H), 8.15 (d, J = 7.4 Hz, 1H),
8.89 (d, J = 8.7 Hz, 1H), 8.89 (d, J = 8.7 Hz, 1H), 9.08 (broad s, 1H). 13C
NMR (75.5 MHz, CDCl3) δ 14.40, 61.41, 11.60, 118.93, 122.56, 123.23,
123.77, 124.28, 125.73, 125.93, 126.29, 126.95, 127.93, 128.50, 129.23,
131.06, 131.52, 135.25, 136.60, 142.23, 167.40, 192.11.
Ethyl 4-[(1-Pentyl-1H-indol-3-yl)carbonyl]naphthalene-1-carbox-
ylate (1-4c). Yield (6.7 g, 36%). 1HNMR (300MHz, CDCl3) δ 0.84 (t, J
= 6.8 Hz, 3H), 1.16−1.36 (m, 4H), 1.49 (t, J = 7.1 Hz, 3H), 1.71−1.85
(m, 2H), 4.04 (t, J = 7.2 Hz, 2H), 4.52 (q, J = 7.1 Hz, 2H), 7.27 (s, 1H),
7.32−7.45 (m, 3H), 7.46−7.53 (m, 1H), 7.58−7.69 (m, 2H), 8.14 (d, J =
8.2 Hz, 1H), 8.19 (d, J = 7.1 Hz, 1H), 8.43−8.53 (m, 1H) 8.92 (d, J = 8.6
Hz, 1H). 13C NMR (75.5 MHz, CDCl3) δ 13.84, 14.43, 22.15, 28.91,
29.45, 47.26, 61.36, 110.08, 117.41, 122.91, 123.10, 123.72, 123.81,
125.92, 126.48, 126.79, 126.87, 127.91, 128.59, 129.01, 131.18, 131.57,
137.12, 138.09, 143.65, 167.47, 191.31. HPLC 97% (Waters X-Bridge
C-18 5 μm, 4.6 mm × 100 mm column, 10 mM aqueous NH4OAc-
CH3CN, 40:60, UV detection at 254 nm). HRMS: calculated for
C27H28NO3 (M + H) 414.2069, found 414.2063 (M + H).
N-(3-Ethoxycarbonylpropyl)-3-(1-naphthoyl)-1H-indole (1-4d).
To a vacuum-dried flask under N2 was added NaH (60% dispersion in
oil, 9.1 mmol, 0.37 mg) and the flask was cooled to 0 °C and dry DMF
(29mL) was added. Themixture was stirred for 10 min and a solution of
3-(1-naphthoyl)indole16 (2.0 g, 0.00729 mol) in DMF (28 mL) was
added dropwise over 30 min. After complete addition, the mixture was
stirred an additional 30 min and then a solution of ethyl bromobutyrate
(3.55 g, 0.0182 mol) in 14 mL of DMF was added over 15 min and the
reaction mixture was allowed to warm to room temperature overnight.
TLC (SiO2; hexane/EtOAc (10:1)) showed the consumption of
starting material. The DMF was removed under reduced pressure, and
the resulting residue was partitioned between water (100 mL) and
EtOAc (3 × 100 mL) followed by CH2Cl2 (2 × 100 mL). The organics
were combined, the solvent removed in vacuo, and the residual material
was chromatographed on an Isco 80 g silica column eluting with a
gradient from hexanes (100%) to hexane/EtOAc (7:3) that afforded the
desired compound in 92% yield. 1H NMR (300 MHz, CDCl3) δ 1.08 (t,
J = 7.13 Hz, 3H), 1.93−2.08 (m, 2H), 2.10−2.22 (m, 2H), 3.91−4.11
(m, 4H), 7.19−7.48 (m, 7H), 7.55 (d, J = 6.9 Hz, 1H), 7.80 (d, J = 7.5
Hz, 1H), 7.86 (d, J = 8.2 Hz, 1H), 8.09 (d, J = 8.0 Hz, 1H), 8.37−8.47
(m, 1H). 13C NMR (75.5 MHz, CDCl3) δ 14.11, 24.97, 30.77, 46.05,
60.68, 109.92, 117.89, 122.98, 123.01, 123.80, 124.54, 125.82, 125.95,
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126.28, 126.76, 127.01, 128.17, 130.01, 130.79, 133.77, 137.00, 137.80,
139.00, 172.31, 192.00.
N-(3-Ethoxycarbonylbutyl)-3-(1-naphthoyl)-1H-indole (1-4e).
Prepared as for the ethoxycarbonylpropyl analogue 1-4d from ethyl
bromovalerate (0.160 mL, 1.014 mmol) afforded 85% of the title
compound. 1H NMR (300 MHz, CDCl3) δ 1.09 (t, J = 7.1 Hz, 3H),
1.41−1.55 (m, 2H), 1.65−1.81 (m, 2H), 2.16 (t, J = 7.2 Hz, 3H), 3.90−
4.06 (m, 4H), 7.21−7.48 (m, 7H), 7.55 (d, J = 7.0 Hz, 1H), 7.79 (d, J =
7.7Hz, 1H), 7.85 (d, J = 8.2Hz, 1H), 8.09 (d, J = 8.1Hz, 1H), 8.36−8.44
(m, 1H). 13C NMR (75.5 MHz, CDCl3) δ 14.17, 22.14, 29.21, 33.52,
46.82, 60.43, 109.87, 117.77, 122.91, 123.02, 123.70, 124.56, 125.84,
125.98, 126.28, 126.75, 127.05, 128.17, 129.98, 130.81, 133.78, 136.99,
137.69, 139.07, 172.81, 191.97
N-(3-Carboxypropyl)-3-(1-naphthoyl)-1H-indole (1-4f). Ester 1-4d
(50 mg) was then treated with sodium hydroxide and water:methanol
(1:1) mixture and heated to 50 °C for 2 h. Cooling and treatment with 2
NHCl, extraction with ethyl acetate, and drying with magnesium sulfate
followed by filtration and concentration provided the desired acid for
testing purposes in yields of 96%. 1H NMR (300 MHz, 3acetonitrile-d3)
δ 1.96−2.10 (m, 2H), 2.17−2.29 (m, 2H), 4.19 (d, J = 7.1 Hz, 2H),
7.30−7.43 (m, 2H), 7.46−7.63 (m, 5H), 7.67−7.75 (m, 1H), 7.95−8.14
(m, 3H), 8.36−8.46 (m, 1H). 13C NMR (75.5 MHz, acetonitrile-d3) δ
24.44, 29.66, 45.47, 110.35, 116.70, 121.84, 122.35, 123.23, 124.55,
125.26, 125.64, 126.01, 126.41, 126.64, 127.97, 129.46, 130.27, 133.46,
136.91, 138.69, 138.75, 172.89, 191.34. EIMS: calculated for
C23H19NO3 357.40, found 358.4 (M + H).
N-(3-Carboxybutyl)-3-(1-naphthoyl)-1H-indole (1-4g). Prepared as
for the above carboxypropyl analogue from the corresponding ester in
78% yield. 1H NMR (300 MHz, CDCl3) δ 1.45−1.58 (m, 2H), 1.71−
1.84 (m, 2H), 2.24 (t, J = 7.2 Hz, 2H), 3.97−4.05 (m, 2H), 7.24−7.48
(m, 7H), 7.57 (d, J = 6.7 Hz, 1H), 7.78−7.92 (m, 2H), 8.10 (d, J = 8.1
Hz, 1H), 8.37−8.44 (m, 1H). 13C NMR (75.5 MHz, CDCl3) δ 21.84,
29.11, 33.14, 46.75, 109.85, 117.77, 122.97, 123.01, 123.74, 124.56,
125.87, 125.94, 126.26, 126.76, 127.00, 128.17, 130.03, 130.77, 133.74,
136.97, 137.77, 138.96, 178.13, 192.14. EIMS: calculated for
C24H21NO3 371.43, found 372.1 (M + H).
X-Fluoro-3-[(naphthalen-1-yl)carbonyl]-1-alkyl-1H-indole (X = 4−
7) (1-4h−m). These analogues were prepared by the same method
described for 1-4h on the same or 55, 55, 59, and 25% scale (1-4k−n).
4-Fluoro-3-[(naphthalen-1-yl)carbonyl]-1-pentyl-1H-indole (1-
4h). Sodium hydride (207 mg, 60% in oil, 5.18 mmol) was added to
DMF (20 mL) at 0 °C and the mixture stirred for 10 min. A solution of
4-fluoro-3-[(naphthalen-1-yl)carbonyl]-1H-indole (1-3e) (750 mg,
2.59 mmol) in DMF (10 mL) was added dropwise over 5 min and
the resulting solution stirred at 0 °C for 30 min. A solution of 1-
bromopentane (431 mg, 2.85 mmol) in DMF (1 mL) was then added
dropwise to the stirred mixture. Cooling was continued for an additional
10 min before allowing the solution to warm to room temperature and
stir overnight. The reaction was quenched with water (75 mL), and
EtOAc (50 mL) was added. The mixture was shaken and the organic
layer removed. The aqueous layer was then extracted with additional
EtOAc (50 mL). The organic layers were combined, dried over Na2SO4,
and the solvent removed under reduced pressure. The residue was
purified over silica gel (Isco, 120 g column, gradient from 100% hexane
to 30% EtOAc/70% hexane) to give the title compound as a colorless
resin (760 mg, 82%). 1H NMR (300 MHz, CDCl3) δ 0.85 (t, J = 6.8 Hz,
3H), 1.15−1.38 (m, 4H), 1.72−1.87 (m, 2H), 4.04 (t, J = 7.2 Hz, 2H),
6.93−7.03 (m, H), 7.16 (d, J = 8.0 Hz, 1H), 7.22−7.30 (m, 1H), 7.33 (s,
1H), 7.43−7.55 (m, 3H), 7.63−7.70 (m, 1H), 7.85−7.93 (m, 1H), 7.97
(d, J = 8.3Hz, 1H), 8.23−8.31 (m, 1H). 13CNMR (75.5MHz, CDCl3) δ
13.83, 22.14, 28.86, 29.32, 47.43, 106.11 (d, J = 4.1 Hz, 1C), 108.48 (d, J
= 21.5 Hz, 1C), 114.91 (d, J = 21.2 Hz, 1C), 117.64 (d, J = 5.8 Hz, 1C),
124.33 (d, J = 8.0 Hz, 1C), 124.41, 126.08, 126.26, 126.75, 126.86,
128.18, 130.40, 131.07, 133.74, 138.12, 139.09 (d, J = 2.7 Hz, 1C),
139.91 (d, J = 11.0 Hz, 1C), 157.03 (d, J = 254.0 Hz, 1C), 190.34. HPLC
99% (Waters X-Bridge C-18 5 μm, 4.6 mm × 100 mm column, H2O−
CH3CN, 35:65, UV detection at 254 nm). HRMS: calculated for
C24H23NOF (M + H) 360.1764, found 360.1760 (M + H).
5-Fluoro-3-[(naphthalen-1-yl)carbonyl]-1-pentyl-1H-indole (1-
4i). Colorless resin (760 mg, 81%). 1H NMR (300 MHz, CDCl3) δ
0.85 (t, J = 6.8 Hz, 3H), 1.17−1.38 (m, 4H), 1.71−1.88 (m, 2H), 4.05 (t,
J = 7.2 Hz, 2H), 7.04−7.14 (m, 2H), 7.37 (s, 1H), 7.43−7.57 (m, 3H),
7.61−7.68 (m, 1H), 7.87−7.94 (m, 1H), 7.98 (d, J = 8.2 Hz, 1H), 8.13−
8.21 (m, 1H), 8.39−8.48 (m, 1H). 13C NMR (75.5 MHz, CDCl3) δ
13.83, 22.14, 28.89, 29.48, 47.46, 108.33 (d, J = 24.8 Hz, 1C), 110.76 (d,
J = 9.8 Hz, 1C), 112.00 (d, J = 26.7 Hz, 1C), 117.50 (d, J = 4.5 Hz, 1C),
124.54, 125.82, 125.91, 126.36, 126.84, 127.75 (d, J = 11.7 Hz, 1C),
128.21, 130.12, 130.76, 133.57, 133.80, 138.68, 138.84, 159.92 (d, J =
238.7 Hz, 1C), 191.73. HPLC 99% (Waters X-Bridge C-18 5 μm, 4.6
mm × 100 mm column, H2O−CH3CN, 35:65, UV detection at 254
nm). HRMS: calculated for C24H23NOF (M + H) 360.1764, found
360.1763 (M + H).
6-Fluoro-3-[(naphthalen-1-yl)carbonyl]-1-pentyl-1H-indole (1-
4j). Colorless resin (840 mg, 90%). 1H NMR (300 MHz, CDCl3) δ
0.85 (t, J = 6.8 Hz, 3H), 1.18−1.40 (m, 4H), 1.72−1.87 (m, 2H), 4.00 (t,
J = 7.2 Hz, 2H), 7.02−7.16 (m, 2H), 7.32 (s, 1H), 7.43−7.58 (m, 3H),
7.61−7.69 (m, 1H), 7.87−7.95 (m, 1H), 7.98 (d, J = 8.2 Hz, 1H), 8.14−
8.22 (m, 1H), 8.39−8.48 (m, 1H). 13C NMR (75.5 MHz, CDCl3) δ
13.82, 22.15, 28.88, 29.35, 47.32, 96.64 (d, J = 26.9 Hz, 1C), 111.34 (d, J
= 23.9 Hz, 1C), 117.70, 123.38, 124.09 (d, J = 10.1 Hz, 1C), 124.51,
125.89, 125.93, 126.35, 126.83, 128.21, 130.13, 130.80, 133.79, 137.31
(d, J = 11.6 Hz, 1C), 138.13 (d, J = 2.9 Hz, 1C), 138.83, 160.57 (d, J =
241.0 Hz, 1C), 191.88. HPLC 99% (Waters X-Bridge C-18 5 μm, 4.6
mm × 100 mm column, H2O−CH3CN, 35:65, UV detection at 254
nm). HRMS: calculated for C24H23NOF (M + H) 360.1764, found
360.1758 (M + H).
7-Fluoro-3-[(naphthalen-1-yl)carbonyl]-1-pentyl-1H-indole (1-
4k). Colorless resin (430 mg, 83%). 1H NMR (300 MHz, CDCl3) δ
0.85 (t, J = 6.7 Hz, 3H), 1.17−1.38 (m, 4H), 1.72−1.88 (m, 2H), 4.20 (t,
J = 7.2 Hz, 2H), 6.97−7.08 (m, 1H), 7.20−7.31 (m, 2H), 7.43−7.58 (m,
3H), 7.61−7.68 (m, 1H), 7.87−7.94 (m, 2H), 8.13−8.21 (m, 1H), 8.27
(d, J = 8.0 Hz, 1H). 13C NMR (75.5 MHz, CDCl3) δ 13.84, 22.14, 28.65,
30.83 (d, J = 2.0 Hz, 1C), 50.0 (d, J = 5.1 Hz, 1C), 109.47 (d, J = 18.2 Hz,
1C), 118.02, 118.67 (d, J = 3.6 Hz, 1C), 123.31 (d, J = 6.5 Hz, 1C),
124.54, 124.88 (d, J = 7.5 Hz, 1C), 125.91 (2C), 126.37, 126.86, 128.22,
130.18, 130.72, 130.76, 133.79, 138.89, 139.08, 149.89 (d, J = 245.3 Hz,
1C), 191.89. HPLC 99% (Waters X-Bridge C-18 5 μm, 4.6 mm × 100
mm column, H2O−CH3CN, 35:65, UV detection at 254 nm). HRMS:
calculated for C24H23NOF (M + H) 360.1764, found 360.1763 (M +
H).
4-Fluoro-1-(5-fluoropentyl)-3-[(naphthalen-1-yl)carbonyl]-1H-in-
dole (1-4l). Colorless resin (150 mg, 28%). 1H NMR (300 MHz,
CDCl3) δ 1.32−1.46 (m, 2H), 1.55−1.76 (m, 2H), 1.77−1.92 (m, 2H),
4.07 (t, J = 7.2 Hz, 2H), 4.29 (t, J = 7.2 Hz, 1H), 4.45 (t, J = 5.8 Hz, 1H),
6.93−7.03 (m, 1H), 7.16 (d, J = 8.1 Hz, 1H), 7.22−7.31 (m, 1H), 7.33
(s, 1H), 7.43−7.55 (m, 3H), 7.63−7.69 (m, 1H), 7.85−7.92 (m, 1H),
7.96 (d, J = 8.2 Hz, 1H), 8.22−8.29 (m, 1H). 13C NMR (75.5 MHz,
CDCl3) δ 22.76 (d, J = 4.9 Hz, 1C), 29.31, 29.82 (d, J = 19.8 Hz, 1C),
47.27, 83.51(d, J = 165.1 Hz, 1C), 106.04 (d, J = 4.0Hz, 1C), 108.54 (d, J
= 21.3 Hz, 1C), 114.92 (d, J = 21.2 Hz, 1C), 117.79 (d, J = 5.8 Hz, 1C),
124.43, 124.45 (d, J = 7.8 Hz, 1C), 126.04, 126.28, 126.79, 126.87,
128.21, 130.46, 131.05, 133.75, 137.99, 139.00 (d, J = 2.8 Hz, 1C),
139.85 (d, J = 11.0 Hz, 1C), 157.05 (d, J = 254.3 Hz, 1C), 190.31. HPLC
98% (Waters X-Bridge C-18 5 μm, 4.6 mm × 100 mm column, H2O−
CH3CN, 35:65, UV detection at 254 nm). HRMS: calculated for
C24H22NOF2 (M + H) 378.1669, found 378.1671 (M + H).
4-Fluoro-1-[2-(morpholin-4-yl)ethyl]-3-[(naphthalen-1-yl)-
carbonyl]-1H-indole (1-4m). Light-yellow liquid (420 mg, 69%). 1H
NMR (300 MHz, CDCl3) δ 2.34 (t, J = 4.6 Hz, 4H), 2.65 (t, J = 6.2 Hz,
2H), 3.49 (t, J = 4.5 Hz, 4H), 4.11 (t, J = 6.2 Hz, 2H), 6.95−7.04 (m,
1H), 7.15 (d, J = 8.1 Hz, 1H), 7.21−7.32 (m, 1H), 7.42 (s, 1H), 7.39−
7.55 (m,3H), 7.62−7.69 (m, 1H), 7.86−7.93 (m, 1H), 7.96 (d, J = 8.0
Hz, 1H), 8.19−8.27 (m, 1H). 13C NMR (75.5 MHz, CDCl3) δ 42.10,
51.32 (2C), 55.01, 64.54 (2C), 103.57 (d, J = 3.8 Hz, 1C), 106.39 (d, J =
21.3 Hz, 1C), 112.48 (d, J = 21.3 Hz, 1C), 115.46 (d, J = 5.9 Hz, 1C),
122.13, 122.25, 123.79, 124.06, 124.27, 124.62, 125.97, 128.07, 128.77,
131.48, 136.91 (d, J = 2.7 Hz, 1C), 137.12, 137.70 (d, J = 11.1 Hz, 1C),
154.85 (d, J = 254.3 Hz, 1C), 188.03. HPLC 99% (Waters X-Bridge C-
18 5 μm, 4.6 mm × 100 mm column, 10 mM aqueous NH4OAc-
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CH3CN, 45:55, UV detection at 254 nm). HRMS: calculated for
C25H24N2O2F (M + H) 403.1822, found 403.1830 (M + H).
4-Fluoro-1-(5-fluoropentyl)-3-[(4-propylnaphthalen-1-yl)-
carbonyl]-1H-indole (1-4n). Light-yellow liquid (68 mg, 24%). 1H
NMR (300MHz, CDCl3) δ 1.06 (t, J = 7.3 Hz, 3H), 1.33−1.46 (m, 2H),
1.56−1.75 (m, 2H), 1.76−1.91 (m, 4H), 3.11 (t, J = 7.5 Hz, 2H), 4.07 (t,
J = 7.1 Hz, 2H), 4.30 (t, J = 5.8 Hz, 1H), 4.46 ((t, J = 5.9 Hz, 1H), 6.94−
7.03 (m, 1H), 7.16 (d, J = 8.1 Hz, 1H), 7.23−7.29 (m, 1H), 7.30−7.37
(m, 2H), 7.43−7.57 (m, 2H), 7.58−7.62 (m, 2H), 8.11 (d, J = 8.0 Hz,
1H), 8.28−8.36 (m, 1H). 13C NMR (75.5 MHz, CDCl3) δ 14.29, 22.77
(d, J = 5.0 Hz, 1C), 29.33, 29.83 (d, J = 19.7 Hz, 1C), 35.50, 47.24, 83.51
(d, J = 165.1 Hz, 1C), 105.97 (d, J = 3.9 Hz, 1C), 108.33, 108.61, 115.01
(d, J = 21.2 Hz, 1C), 117.97 (d, J = 5.8 Hz, 1C), 118.01, 124.03, 124.36
(d, J = 7.9 Hz, 1C), 124.50, 126.01, 126.33, 126.80, 126.82, 131.49,
132.21, 137.35 (d, J = 2.6 Hz, 1C), 139.76, 139.90, 141.66, 157.08 (d, J =
254.4 Hz, 1C), 190.54. HPLC 99% (Waters X-Bridge C-18 5 μm, 4.6
mm × 100 mm column, H2O−CH3CN, 35:65, UV detection at 254
nm). HRMS: Calculated for C27H28NOF2 (M + H) 420.2139, found,
420.2151 (M + H).
4-(2-Iodoethyl)morpholine (1-5, X = I). 4-(2-Chloroethyl)-
morpholine hydrochloride (5 g, 0.0269 mol) and sodium iodide (20
g, 0.1334 mol) were placed in acetone (50 mL) and refluxed for 16 h.
Chloroform (50 mL) and brine solution (50 mL) were then added and
the mixture stirred for 10 min. The solid was removed by filtration and
added to a mixture of chloroform (50 mL) and saturated sodium
bicarbonate solution (50mL). The mixture was stirred for 5 min and the
organic layer removed. The aqueous layer was then extracted with
additional chloroform (2 × 25 mL). The organic layers were combined,
washed with brine, and dried over sodium sulfate. The solvent was
removed under reduced pressure to give the title product as a yellow oil
(3.05 g, 47%), which contained approximately 5% 4-(2-chloroethyl)-
morpholine. 1H NMR (300 MHz, CDCl3) δ 2.49 (t, J = 4.7 Hz, 4H),
2.72 (t, J = 7.6 Hz, 2H), 3.21 (t, J = 7.6 Hz, 2H), 3.71 (t, J = 4.7 Hz, 4H).
4-[(1-Pentyl-1H-indol-3-yl)carbonyl]naphthalene-1-carboxylic
Acid (1-7a). Ethyl 4-[(1-pentyl-1H-indol-3-yl)carbonyl]naphthalene-1-
carboxylate (1-4c) (3.0 g, 0.0073 mol) was dissolved in dioxane (50
mL). Sodium hydroxide solution (5N, 50 mL) was added and the
mixture refluxed for 3 h. The solution was then allowed to cool to room
temperature and stir overnight. The layers were separated and the
solvent removed from the organic layer. The resulting residue was
dissolved in water (50 mL) and extracted with EtOAc (2 × 50 mL) to
remove unreacted starting material. The pH of the aqueous layer was
then adjusted to 3 by the addition of HCl solution (1N) and extracted
with EtOAc (2 × 50 mL). The organic layers were combined and dried
over sodium sulfate. The solvent was removed under reduced pressure
to give the title compound as a golden foam (2.05 g, 73%). 1H NMR
(300MHz, CDCl3) δ 0.85 (t, J = 6.7Hz, 3H), 1.18−1.38 (m, 4H), 1.74−
1.87 (m, 2H), 4.06 (t, J = 6.7 Hz, 2H), 7.31 (s, 1H), 7.34−7.45 (m, 3H),
7.48−7.57 (m, 1H), 7.63−7.72 (m, 2H), 8.17 (d, J = 8.4 Hz, 1H), 8.43
(d, J = 7.4 Hz, 1H), 8.45−8.53 (m, 1H), 9.11 (d, J = 8.7 Hz, 1H), OH
proton not observed.
N-Methyl-4-[(1-pentyl-1H-indol-3-yl)carbonyl]naphthalene-1-
carboxamide (1-7b). 4-[(1-Pentyl-1H-indol-3-yl)carbonyl]-
naphthalene-1-carboxylic acid (1-7a) (830 mg, 2.15 mmol) was
dissolved in THF (50 mL) and cooled in an ice bath. Oxalyl chloride
(0.6 mL) was then added dropwise to the stirred solution under
nitrogen. After the addition was complete (2 min), the mixture was
stirred an additional 10 min at 0 °C and then at room temperature
overnight. Subsequently, the solvent was removed under reduced
pressure and the residue redissolved in THF (50 mL). The resulting
solution was cooled to 0 °C in an ice bath, aqueous methylamine (1.5
mL, 40%) added, and the mixture stirred at 0 °C for 15min. The ice bath
was removed and the solution stirred at room temperature for 5 min.
The solvent was removed under reduced pressure and the residue
partitioned between EtOAc (75 mL) and water (75 mL). The organic
layer was removed and the aqueous layer extracted with additional
EtOAc (50 mL). The organic layers were combined, washed with brine,
and dried over anhydrous sodium sulfate. The solvent was removed
under reduced pressure and the residue purified over silica gel (Isco,
gradient from 100% hexane to 60% EtOAc/40% hexane) to give the title
compound as a golden foam (750 mg, 87%). 1H NMR (300 MHz,
CDCl3) δ 0.83 (t, J = 6.8 Hz, 3H), 1.15−1.35 (m, 4H), 1.71−1.83 (m,
2H), 3.12 (d, J = 4.9 Hz, 3H), 4.03 (t, J = 7.1 Hz, 2H), 6.44−6.55 (m,
1H), 7.23 (s, 1H), 7.32−7.52 (m, 7H), 8.08 (d, J = 8.3Hz, 1H), 8.26 (d, J
= 8.6 Hz, 1H), 8.43−8.52 (m, 1H). 13C NMR (75.5 MHz, CDCl3) δ
13.84, 22.14, 26.90, 28.90, 29.40, 47.24, 110.10, 117.36, 122.82, 123.08,
123.61, 123.78, 124.08, 125.65, 126.23, 126.79, 127.06, 127.35, 130.36,
130.97, 136.20, 137.12, 138.44, 141.23, 170.08, 191.58. HPLC 98%
(Waters X-Bridge C-18 5 μm, 4.6 mm × 100 mm column, 10 mM
aqueous NH4OAc−CH3CN, 40:60, UV detection at 254 nm). HRMS:
calculated for C26H27N2O2 (M + H) 399.2073, found 399.2069 (M +
H).
4-[(1-Pentyl-1H-indol-3-yl)carbonyl]naphthalene-1-carboxamide
(1-7c). Prepared as for 1-7b with aqueous ammonium hydroxide (1.5
mL, 30%) and similarly chromatographed on silica gel (Isco, gradient
from 100% hexane to 70% EtOAc/30% hexane) to give the title
compound as a white solid (810 mg, 81%). 1H NMR (300 MHz,
CDCl3) δ 0.83 (t, J = 6.6 Hz, 3H), 1.14−1.36 (m, 4H), 1.70−1.84 (m,
3H), 4.03 (t, J = 7.2 Hz, 2H), 6.27 (broad s, 1H), 6.47 (broad s, 1H),
7.25 (s, 1H), 7.31−7.61 (m, 6H), 7.68 (d, J = 7.2Hz, 1H), 8.10 (d, J = 8.4
Hz, 1H), 8.38 (d, J = 8.3 Hz, 1H), 8.43−8.52 (m, 1H). 13C NMR (75.5
MHz, CDCl3) δ 13.84, 22.14, 28.89, 29.41, 47.26, 110.11, 117.34,
122.83, 123.12, 123.82, 123.99, 124.06, 125.63, 126.32, 126.78, 127.16,
127.56, 130.27, 131.04, 134.80, 137.13, 138.37, 141.75, 171.40, 191.43.
HPLC 98% (Waters X-Bridge C-18 5 μm, 4.6 mm × 100 mm column,
10 mM aqueous NH4OAc−CH3CN, 40:60, UV detection at 254 nm).
HRMS: calculated for C25H25N2O2 (M + H) 385.1916, found 385.1920
(M + H).
1-{4-[ (1-Penty l-1H-indol-3-yl )carbonyl]naphthalen-1-
yl}34propan-1-one (1-7d). 4-[(1-Pentyl-1H-indol-3-yl)carbonyl]-
naphthalene-1-carboxylic acid (1-7a) (830 mg, 2.15 mmol) was
dissolved in THF (40 mL). DMF (0.2 mL) was added and the mixture
purged with nitrogen. Oxalyl chloride (0.8 mL) was then added
dropwise to the stirred solution over several minutes. After the addition
was complete, themixture was stirred at room temperature overnight. At
the end of this time, themixture was filtered to remove a small amount of
solid material and the solvent removed from the filtrate under reduced
pressure. The residue was dissolved in toluene (40 mL), and the
resulting solution was cooled to 0 °C in a ice bath. Diethyl zinc (5.18mL,
1 M in hexanes, 5.18 mmol) was then added over 2 min and the mixture
stirred at 0 °C for an additional 10 min. The ice bath was removed and
the solution stirred at room temperature for 4.5 h. The reaction was
quenched with saturated ammonium chloride solution (40 mL total)
and EtOAc (40 mL) was added. The mixture was stirred for 20 min, the
organic layer removed, and the aqueous layer extracted with additional
EtOAc (40 mL). The organic layers were combined, and the solvent was
removed under reduced pressure. The reaction was repeated using 410
mg of 1-7a (1.24 g total between the two reactions) and the material
from both reactions combined. The residue was initially purified over
silica gel (Isco, 120 g column, gradient from 100% hexane to 30%
EtOAc/70% hexane) and subsequently twice by preparative thin layer
chromatography (silica, 20 cm × 20 cm plate, 1000 μm, dichloro-
methane). A final purification by preparative thin layer chromatography
(15% EtOAc/85% hexane) afforded the title compound as an off-white
solid (two fractions: 11.6 mg, 98% pure by HPLC, 0.91%; 6.2 mg, 98%
pure by HPLC, 0.48%). 1H NMR (300 MHz, CDCl3) δ 0.83 (t, J = 6.7
Hz, 3H), 1.19−1.37 (m, 4H), 1.32 (t, J = 7.2 Hz, 3H),1.73−1.86 (m,
2H), 3.12 (q, J = 7.3 Hz, 2H), 4.05 (t, J = 7.2 Hz, 2H), 7.28 (s, 1H),
7.32−7.43 (m, 3H), 7.44−7.53 (m, 1H), 7.54−7.66 (m, 2H), 7.82 (d, J =
7.3 Hz, 1H), 8.13 (d, J = 8.4 Hz, 1H), 8.42−8.52 (m, 2H). 13C NMR
(75.5 MHz, CDCl3) δ 8.58, 13.83, 22.14, 28.91, 29.45, 35.91, 47.26,
110.06, 117.39, 122.91, 123.10, 123.70, 123.81, 125.15, 125.76, 126.43,
126.79. 127.08, 127.93, 130.30. 131.30, 137.12, 138.11, 138.21, 142.73.
191.29, 205.75. HPLC (Waters X-Bridge C-18 5 μm, 4.6 mm × 100 mm
column, H2O−CH3CN, 35:65, UV detection at 254 nm). HRMS:
calculated for C27H28NO2 (M +H) 398.2120; found 398.2131 (M +H).
4-[2-(1H-Inden-3-yl)ethyl]morpholine (2-3). Indene (2−1) (10 g,
0.086 mol) was dissolved in anhydrous THF (130 mL) and the solution
cooled in a dry ice/acetonitrile bath. nBuLi (0.0538 L, 1.6 M in hexane,
0.0861 mol) was then added dropwise over 10 min. The cooling was
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continued for 10min, the bath removed, and the solution stirred at room
temperature for 20 min. The mixture was again cooled in a dry ice/
acetonitrile bath and 4-(2-chloroethyl)morpholine (2-2) (12.89 g,
0.0861 mmol) added dropwise over 10 min. The cooling was continued
for 10 min, the bath removed, and the solution stirred overnight at room
temperature. The mixture was quenched with methanol (20 mL) and
the solvent removed under reduced pressure. The residue was
partitioned between CH2CL2 (50 mL) and water (50 mL). The organic
layer was removed and the aqueous layer extracted with additional
CH2Cl2 (50 mL). The organic layers were combined, filtered through
Celite, and the solvent removed under reduced pressure to give a crude
mixture of (1-yl) and (3-yl 2-3). The residue was dissolved in dioxane
(75 mL) and NaOH solution (4N, 75 mL) added to the mixture. The
resulting solution was then heated under reflux for 5 h. Subsequently, the
organic layer was removed and EtOAc (50 mL) and water (50 mL)
added to the aqueous layer. The resulting mixture was shaken, the
organic layer removed, and the aqueous layer extracted with additional
EtOAc (2 × 25 mL). The organic layers were combined, washed with
water, and dried over sodium sulfate. The solvent was removed under
reduced pressure and residue was columned over silica gel (Isco,
gradient from 100% hexane to 80% EtOAc/20% hexane) to give
recovered indene (890 mg) and the title product (2-3) as a yellow oil
(8.92 g, 45%). 1H NMR (300 MHz, CDCl3) δ 2.56 (t, J = 4.6 Hz, 4H),
2.66−2.83 (m, 4H), 3.33 (d, J = 4.7 Hz, 2H), 3.77 (t, J = 4.7 Hz, 4H),
6.26 (s, 1H), 7.17−7.24 (m, 1H), 7.26−7.34 (m, 1H), 7.35−7.41 (m,
1H), 7.46 (d, J = 7.3 Hz, 1H).
4-Ethylnaphthalene-1-carbaldehyde (2-4t). Prepared as for 2-4u in
51% yield. Light-brown oil. 1H NMR (300 MHz, CDCl3) δ 1.41 (t, J =
7.5Hz, 3H), 3.18 (q, J = 7.5Hz, 2H), 7.50 (d, J = 7.3Hz, 1H), 7.55−7.70
(m, 2H), 7.90 (d, J = 7.3 Hz, 1H), 8.13 (d, J = 8.5 Hz, 1H), 9.33 (d, J =
8.4 Hz, 1H), 10.33 (s, 1H).
4-Propylnaphthalene-1-carbaldehyde (2-4u). Dichloromethyl
methyl ether (0.39 mL, 97%, 4.2 mmol) was dissolved in dichloroethane
(5 mL) and cooled to 0 °C. TiCl4 (0.46 mL, 4.2 mmol) was added
dropwise over 2 min. Once the addition was complete, the solution was
stirred at 0 °C for 45min. 1-Propyl naphthalene (550 mg, 3.23 mmol) in
dichloroethane (5 mL) was then added dropwise over 5 min. The
solution was allowed to warm to room temperature and stirred
overnight. The reaction mixture was then poured into ice−water (100
mL), the organic layer removed, and the aqueous layer extracted with
dichloroethane (2× 25mL). The organic layers were combined, washed
with saturated sodium bicarbonate solution and water, and dried over
sodium sulfate. The solvent was removed under reduced pressure, and
the residue was columned over silica gel (Isco, gradient from 100%
hexane to 10% EtOAc/90% hexane) to give the title product as a light-
brown oil (480 mg, 75%). 1HNMR (300MHz, CDCl3) δ 1.05 (t, J = 7.4
Hz, 3H), 1.74−1.88 (m, 2H), 3.11 (t, J = 7.5 Hz, 2H), 7.47 (d, J = 7.3 Hz,
1H), 7.57−7.71 (m, 2H), 7.89 (d, J = 7.3 Hz, 1H), 8.09−8.16 (m, 1H),
9.30−9.37 (m, 1H), 10.33 (s, 1H).
4-{2-[(1E)-1-(Arylidene)-1H-inden-3-yl]ethyl}morpholine (2-5a−2-
5u). Method 1 (2-5a−e): Reflux 18 h or Method 2 (2-5f−u):
Microwave for 15−17 min; with variations in purification of the reaction
residue after cooling and evaporation that were either recrystallization or
silica gel chromatography typified by preparation of 2-5d (method 1) or
2-5h (method 2).
4-{2-[(1E)-1-[(2-Fluorophenyl)methylidene]-1H-inden-3-yl]ethyl}-
morpholine (2-5d): Method 1.Method 1: 4-[2-(1H-Inden-3-yl)ethyl]-
morpholine (2-3) (260 mg, 1.13 mmol) was dissolved in methanol (1.0
mL) and the reaction mixture purged with nitrogen. Sodium methoxide
(2.50 mL, 0.5M inMeOH; 1.25 mmol) was added dropwise over 5 min,
and the solution stirred for 10 min. 2-Fluorobenzaldehyde (0.14 mL,
97%, 1.29 mmol) was added dropwise and the mixture stirred for 5 min.
The solution was then heated under reflux for 18 h then allowed to cool
to room temperature, and the solvent was removed under reduced
pressure. The residue was purified over silica gel (Isco, 120 g column,
100% EtOAc) to give the title compound as a yellow film (76 mg, 93%
pure by HPLC, 20%). A second fraction of less pure material was also
collected (42 mg, 91% pure by HPLC, 11%). 1H NMR (300 MHz,
CDCl3) δ 2.56 (t, J = 4.6 Hz, 4H), 2.68−2.77 (m, 2H), 2.79−2.90 (m,
2H), 3.76 (t, J = 4.7 Hz, 4H), 6.72 (s, 1H), 7.04−7.43 (m, 6H), 7.48 (s,
1H), 7.58−7.74 38 (m, 2H). 13C NMR (75.5 MHz, CDCl3) δ 25.46,
53.75 (2C), 57.49, 67.07 (2C), 115.72 (d, J = 21.9 Hz, 1C), 118.50 (d, J
= 4.6 Hz, 1C), 118.74, 119.38, 121.91, 124.16 (d, J = 3.6 Hz, 1C) 125.21
(d, J = 13.4 Hz, 1C), 125.62, 127.70, 129.77 (d, J = 8.4 Hz, 1C), 131.66
(d, J = 2.8 Hz, 1C), 137.90, 140.84, 142.43, 147.25, 161.09 (d, J = 250.1
Hz, 1C). HPLC (Waters X-Bridge C-18 5 μm, 4.6 mm × 100 mm
column, 10 mM aqueous NH4OAc−CH3CN, 40:60, UV detection at
254 nm). HRMS: calculated for C22H23NOF (M + H) 336.1764, found
336.1763 (M + H).
4-{2-[(1E)-1-(Naphthalen-1-ylmethylidene)-1H-inden-3-yl]ethyl}-
morpholine (2-5a). Golden solid (2.98 g, 66%). 1H NMR (300 MHz,
CDCl3) δ 2.41 (t, J = 4.2 Hz, 4H), 2.54−2.64 (m, 2H), 2.71−2.82 (m,
2H), 3.56 (t, J = 4.5 Hz, 4H), 3H), 6.67 (s, 1H), 7.26−7.41 (m, 3H),
7.55−7.71 (m, 4H), 7.93−8.08 (m, 3H), 8.22−8.31 (m, 2H). 13C NMR
(75.5 MHz, CDCl3) δ 24.65, 53.15 (2C), 56.74, 66.20 (2C), 118.76,
119.86, 122.11, 124.44, 124.52, 125.32, 125.65, 126.22, 126.55, 127.54,
128.47, 128.51, 128.87, 131.58, 133.21, 133.54, 137.31, 140.67, 142.28,
146.74. HPLC 99% (Waters X-Bridge C-18 5 μm, 4.6 mm × 100 mm
column, 10 mM aqueous NH4OAc−CH3CN, 40:60, UV detection at
254 nm). HRMS: calculated for C26H26NO (M + H) 368.2014, found
368.2013 (M + H).
4-{2-[(1E)-1-(Phenylmethyl idene)-1H-inden-3-yl]ethyl}-
morpholine (2-5b). Dark-yellow resin (258 mg, 46%). 1H NMR (300
MHz, CDCl3) δ 2.57 (t, J = 4.5 Hz, 4H), 2.70−2.79 (m, 2H), 2.81−
2.91(m, 2H), 3.77 (t, J = 4.7 Hz, 4H, 6.83 (s, 1H), 7.21−7.48 (m, 7H),
7.56−7.63 (m, 2H), 7.66−7.72 (m, 1H). 13C NMR (75.5 MHz, CDCl3)
δ 25.42, 53.75 (2C), 57.57, 67.05 (2C), 118.71, 119.04, 122.06, 125.41,
126.62, 127.39, 128.09, 128.68 (2C), 130.10 (2C), 137.23, 138.24,
139.41, 142.23, 146.58. HPLC 99% (Waters X-Bridge C-18 5 μm, 4.6
mm × 100 mm column, 10 mM aqueous ammonium formate−
acetonitrile, 40:60, UV detection at 254 nm). HRMS: calculated for
C22H24NO (M + H) 318.1858, found 318.1857 (M + H).
4-{2-[(1E)-1-[(2-Iodophenyl)methylidene]-1H-inden-3-yl]ethyl}-
morpholine (2-5c). Yellow solid (1.00 g, 57%). 1H NMR (300 MHz,
CDCl3) δ 2.55 (t, J = 4.6 Hz, 4H), 2.66−2.75 (m, 2H), 2.77−2.87 (m,
2H), 3.75 (t, J = 4.6 Hz, 4H), 3H), 6.57 (s, 1H), 6.98−7.07 (m, 1H),
7.22−7.34 (m, 3H), 7.35−7.47 (m, 2H), 7.52−7.59 (m, 1H), 7.71−7.79
(m, 1H), 7.89−7.97 (m, 1H). 13C NMR (75.5 MHz, CDCl3) δ 25.45,
53.74 (2C), 57.43, 67.06 (2C), 100.92, 118.80, 119.49, 121.87, 125.63,
127.83, 128.12, 129.26, 129.92, 131.65, 137.57, 139.35, 140.52, 140.54,
142.64, 147.05. HPLC 98% (Waters X-Bridge C-18 5 μm, 4.6 mm× 100
mm column, 10 mM aqueous NH4OAc−CH3CN, 40:60, UV detection
at 254 nm). HRMS: calculated for C22H23NOI (M + H) 444.0824,
found 444.0828 (M + H).
4-{2-[(1E)-1-[(3-Phenylphenyl)methylidene]-1H-inden-3-yl]ethyl}-
morpholine (2-5e). Yellow film (21%). 1H NMR (300 MHz, CDCl3) δ
2.56 (t, J = 4.4 Hz, 4H), 2.69−2.79 (m, 2H), 2.80−2.91 (m, 2H), 3.74 (t,
J = 4.6 Hz, 4H), 6.87 (s, 1H), 7.21−7.34 (m, 3H), 7.35−7.73 (m, 10H),
7.79 (s, 1H). 13C NMR (75.5 MHz, CDCl3) δ 25.42, 53.72 (2C), 57.56,
67.03 (2C), 118.78, 119.11, 122.14, 125.48, 126.50, 126.97, 127.23
(2C), 127.48, 127.59, 128.90 (4C), 129.12, 137.73, 138.24, 139.75,
140.90, 141.78, 142.29, 146.80. HPLC 94% (Waters X-Bridge C-18 5
mm, 4.6 mm × 100 mm column, 10 mM aqueous NH4OAc−CH3CN,
35:65, UV detection at 254 nm). HRMS: calculated for C28H28NO (M+
H) 394.2171; found 394.2176 (M + H).
4-{2-[(1E)-1-[(2-Methoxyphenyl)methylidene]-1H-inden-3-yl]-
ethyl}morpholine (2-5h): Methods 2. Method 2: 4-[2-(1H-Inden-3-
yl)ethyl]morpholine (2-3) (260 mg, 1.13 mmol) and methanol (1.5
mL) were placed in a 10 mL microwave tube equipped with a rubber
septa. The system was purged with nitrogen, sodium methoxide (2.30
mL, 0.5 M in MeOH; 1.15 mmol) added dropwise over 5 min and the
solution stirred for 10 min. 2-Methoxybenzaldehyde (0.15 mL, 98%,
1.22 mmol) was added and the mixture stirred for an additional 5 min.
The septa was replaced with a microwave cap and the tube irradiated for
15.0 min at 105 °C. Subsequently, the mixture was allowed to cool to
room temperature and the solvent removed under reduced pressure.
The residue was purified over silica gel (Isco, 120 g column, 100%
EtOAc) to give two fractions of title compound (13 mg, 96% pure by
HPLC, 3.3%; 110 mg, 95% pure by HPLC, 28%). 1H NMR (300 MHz,
CDCl3) δ 2.56 (t, J = 4.5 Hz, 4H), 2.68−2.78 (m, 2H), 2.80−2.90 (m,
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2H), 3.76 (t, J = 4.6 Hz, 4H), 3.90 (s, 3H), 6.75 (s, 1H), 6.94 (d, J = 8.2
Hz, 7.04 (t, J = 5.0 Hz, 1H), 7.18−7.38 (m, 4H), 7.55−7.62 (m, 1H),
7.67 (s,1H), 7.71−7.78 (d, J = 6.7 Hz, 1H). 13C NMR (75.5 MHz,
CDCl3) δ 25.42, 53.76 (2C), 55.59, 57.53, 67.08 (2C), 110.69, 118.53,
119.33, 120.61, 122.38 (2C), 126.36, 127.14, 129.60, 130.19, 131.75,
138.19, 139.18, 142.37, 145.82, 158.20. HPLC (Waters X-Bridge C-18 5
μm, 4.6 mm × 100 mm column, 10 mM aqueous NH4OAc-CH3CN,
40:60, UV detection at 254 nm). HRMS: calculated for C23H25NO2 (M
+ H) 348.1964, found 348.1967 (M + H).
4-{2-[(1E)-1-[(2-Chlorophenyl)methylidene]-1H-inden-3-yl]ethyl}-
morpholine (2-5f). Yield 85 mg, 97% pure by HPLC, 20%. 1H NMR
(300MHz, CDCl3) δ 2.55 (t, J = 4.5Hz, 4H), 2.66−2.76 (m, 2H), 2.78−
2.88 (m, 2H), 3.75 (t, J = 4.7 Hz, 4H), 3H), 6.63 (s, 1H), 7.22−7.37 (m,
5H), 7.42−7.48 (m, 1H), 7.55−7.64 (m,2H), 7.71−7.77 (m, 1H). 13C
NMR (75.5 MHz, CDCl3) δ 25.44, 53.74 (2C), 57.46, 67.06 (2C),
118.77, 119.51, 121.85, 123.09, 125.63, 126.70, 127.82, 129.12, 129.74,
132.21, 134.77, 135.48, 137.72, 140.96, 142.60, 147.29. HPLC (Waters
X-Bridge C-18 5 μm, 4.6 mm × 100 mm column, 10 mM aqueous
NH4OAc−CH3CN, 40:60, UV detection at 254 nm). HRMS: calculated
for C22H23NOCl (M + H) 352.1468, found 352.1455 (M + H).
4-{2-[(1E)-1-[(2-Bromophenyl)methylidene]-1H-inden-3-yl]ethyl}-
morpholine (2-5g). Yield 157 mg, 95% pure by HPLC, 34%. 1H NMR
(300MHz, CDCl3) δ 2.54 (t, J = 4.4Hz, 4H), 2.65−2.75 (m, 2H), 2.76−
2.87 (m, 2H), 3.75 (t, J = 4.7 Hz, 4H), 3H), 6.60 (s, 1H), 7.14−7.42 (m,
5H), 7.50 (s, 1H), 7.55−7.67 (m, 2H), 7.70−7.76 (m, 1H). 13C NMR
(75.5 MHz, CDCl3) δ 25.44, 53.74 (2C), 57.44, 67.06 (2C), 118.77,
119.51, 121.85, 125.08, 125.48, 125.63, 127.29, 127.82, 129.26, 132.33,
132.93, 137.21, 137.66, 140.81, 142.620, 147.21. HPLC (Waters X-
Bridge C-18 5 μm, 4.6 mm × 100 mm column, 10 mM aqueous
NH4OAc−CH3CN, 40:60, UV detection at 254 nm). HRMS: calculated
for C22H23NOBr (M + H) 396.0963, found 396.0959 (M + H).
4-{2-[(1E)-1-[(2-Methylphenyl)methylidene]-1H-inden-3-yl]ethyl}-
morpholine (2-5i). Yield 251 mg, 94% pure by HPLC, 63%. 1H NMR
(300 MHz, CDCl3) δ 2.42 (s, 3H), 2.55 (t, J = 4.2 Hz, 4H), 2.67−2.76
(m, 2H), 2.79−2.89 (m, 2H), 3.76 (t, J = 4.6 Hz, 4H), 6.64 (s, 1H),
7.20−7.36 (m, 6H), 7.45−7.54 (m, 2H), 7.73 (d, J = 6.7 Hz, 1H). 13C
NMR (75.5 MHz, CDCl3) δ 20.13, 25.38, 53.75 (2C), 57.53, 67.06
(2C), 118.68, 119.13, 122.56, 125.30, 125.41, 125.88, 127.45, 128.14,
130.19, 130.94, 136.19, 137.44, 137.78, 139.93, 142.65, 146.01. HPLC
(Waters X-Bridge C-18 5 μm, 4.6 mm × 100 mm column, 10 mM
aqueous NH4OAc−CH3CN, 40:60, UV detection at 254 nm). HRMS:
calculated for C23H26NO (M + H) 332.2014, found 332.2022 (M + H).
4-{2-[(1E)-1-[(4-Methoxynaphthalen-1-yl)methylidene]-1H-
inden-3-yl]ethyl}morpholine (2-5j). Yellow solid (134 mg, 31%). 1H
NMR (300MHz, CDCl3) δ 2.51 (t, J = 4.5 Hz, 4H), 2.64−2.75 (m, 2H),
2.77−2.87 (m, 2H), 3.73 (t, J = 4.6 Hz, 4H), 4.02 (s, 3H), 6.67 (s, 1H),
6.87 (d, J = 8.0 Hz, 1H), 7.25−7.38 (m, 3H), 7.46−7.61 (m, 3H), 7.75−
7.84 (m, 1H), 7.96 (s, 1H), 8.04−8.12 (m, 1H), 8.29−8.38 (m, 1H). 13C
NMR (75.5 MHz, CDCl3) δ 25.41, 53.76 (2C), 56.66, 57.61, 67.07
(2C), 103.76, 118.71, 119.17, 122.62, 122.95, 124.42, 124.61, 125.27,
125.53, 125.67, 126.61, 127.06, 127.29, 129.79, 133.15, 137.84, 139.99,
142.77, 145.42, 156.05. HPLC 95% (Waters X-Bridge C-18 5 μm, 4.6
mm × 100 mm column, 10 mM aqueous ammonium formate−
acetonitrile, 40:60, UV detection at 254 nm). HRMS: calculated for
C27H28NO2 (M + H) 398.2120, found 398.2124 (M + H).
4-{2-[(1E)-1-[(2-Phenylphenyl)methylidene]-1H-inden-3-yl]ethyl}-
morpholine (2-5k). Yellow film (133 mg, 30%). 1H NMR (300 MHz,
CDCl3) δ 2.56 (t, J = 4.4 Hz, 4H), 2.69−2.80 (m, 2H), 2.81−2.92 (m,
2H), 3.76 (t, J = 4.6 Hz, 4H), 6.84 (s, 1H), 7.09−7.18 (m, 1H), 7.22−
7.48 (m, 12H), 7.64−7.73 (m, 1H). 13C NMR (75.5 MHz, CDCl3) δ
25.51, 53.84 (2C), 57.66, 67.12 (2C), 118.66, 119.33, 122.56, 125.34,
127.03, 127.36, 127.38, 127.47, 128.23 (2C), 128.33, 130.02 (2C),
130.12, 131.94, 135.20, 137.94, 139.45, 140.62, 142.42, 146.46, 146.09.
HPLC 92% (Waters X-Bridge C-18 5 μm, 4.6 mm × 100 mm column,
10 mM aqueous NH4OAc−CH3CN, 35:65, UV detection at 254 nm).
HRMS: calculated for C28H28NO (M + H) 394.2171, round 394.2176
(M + H).
7-{[(1E)-3-[2-(Morpholin-4-yl)ethyl]-1H-inden-1-ylidene]methyl}-
1H-indole (2-5l). Yellow film (115 mg, 31%). 1H NMR (300 MHz,
CDCl3) δ 2.49 (t, J = 4.4 Hz, 4H), 2.60−2.72 (m, 2H), 2.73−2.86 (m,
2H), 3.72 (t, J = 4.5 Hz, 4H), 6.55−6.65 (m, 1H), 6.67 (s, 1H), 7.12−
7.40 (m, 6H), 7.57 (s, 1H), 7.60−7.78 (m, 2H), 8.63 (s, 1H). 13C NMR
(75.5 MHz, CDCl3) δ 25.34, 53.71 (2C), 57.46, 67.04 (2C), 103.17,
118.95, 119.20, 120.18, 120.94, 121.32, 122.30, 122.73, 124.14, 124.42,
125.55, 127.56, 128.47, 134.55, 137.81, 140.22, 142.61, 146.31. HPLC
94% (Waters X-Bridge C-18 5 μm, 4.6 mm × 100 mm column, 10 mM
aqueous NH4OAc−CH3CN, 35:65, UV detection at 254 nm). HRMS:
calculated for C24H25N2O (M +H) 357.1967, found 357.1966 (M +H).
4-{2-[(1E)-1-(Thiophen-2-ylmethylidene)-1H-inden-3-yl]ethyl}-
morpholine (2-5m). Yellow solid (235 mg, 67%). 1H NMR (300 MHz,
CDCl3) δ 2.56 (t, J = 4.5 Hz, 4H), 2.68−2.78 (m, 2H), 2.80−2.90 (m,
2H), 3.76 (t, J = 4.6 Hz, 4H), 7.01 (s, 1H), 7.03−7.09 (m, 1H), 7.16−
7.31 (m, 4H), 7.37−7.44 (m, 2H), 7.55−7.64 (m, 2H). 13C NMR (75.5
MHz, CDCl3) δ 25.47, 53.77 (2C), 57.56, 67.10 (2C), 118.90, 118.97
(2C), 121.85, 125.40, 127.11, 127.64, 128.53, 131.03, 136.79, 138.39,
140.96, 142.14, 146.37. HPLC 94% (Waters X-Bridge C-18 5 μm, 4.6
mm× 100 mm column, 10 mM aqueous NH4OAc−CH3CN, 35:65, UV
detection at 254 nm). HRMS: calculated for C20H22NOS (M + H)
324.1422, found 324.1431 (M + H).
4-{2-[(1E)-1-(Furan-2-ylmethylidene)-1H-inden-3-yl]ethyl}-
morpholine (2-5n). Yellow solid (231 mg, 64%). 1H NMR (300 MHz,
CDCl3) δ 2.47−2.53 (m, 4H), 2.70−2.96 (m, 4H), 3.65−3.90 (m, 4H),
6.45−6.55 (m, 1H), 6.57−6.65 (m, 1H), 6.98 (s, 1H), 7.10−7.34 (m,
4H), 7.50−7.64 (m, 2H). 13C NMR (75.5 MHz, CDCl3) δ 25.48, 53.79
(2C), 57.67, 67.08 (2C), 112.26, 112.38, 114.22, 118.81, 118.88, 123.24,
125.18, 127.13, 136.02, 138.19, 142.17, 144.38, 145.68, 153.52. HPLC
94% (Waters X-Bridge C-18 5 μm, 4.6 mm × 100 mm column, 10 mM
aqueous NH4OAc−CH3CN, 40:60, UV detection at 254 nm). HRMS:
calculated for C20H22NO2 (M +H) 308.1651, found 308.1632 (M +H).
5-{[(1E)-3-[2-(Morpholin-4-yl)ethyl]-1H-inden-1-ylidene]methyl}-
isoquinoline (2-5o). Yellow solid (70mg, 17%, 93% pure byHPLC). 1H
NMR (300MHz, CDCl3) δ 2.53 (t, J = 4.5 Hz, 4H), 2.65−2.75 (m, 2H),
2.77−2.88 (m, 2H), 3.74 (t, J = 4.5 Hz, 4H), 6.56 (s, 1H), 7.27−7.40 (m,
3H), 7.62−7.72 (m, 1H), 7.76−7.94 (m, 4H), 7.98 (d, J = 8.1 Hz, 1H),
8.58 (d, J = 5.9 Hz, 1H), 9.30 (s, 1H). 13C NMR (75.5 MHz, CDCl3) δ
25.43, 53.72 (2C), 57.40, 67.03 (2C), 117.53, 118.93, 119.39, 121.97,
122.23, 125.69, 126.88, 127.84, 128.01, 128.78, 132.68, 133.45, 134.84,
137.41, 142.37, 142.89, 143.65, 147.35, 153.09. HPLC (Waters X-Bridge
C-18 5 μm, 4.6 mm × 100 mm column, 10 mM aqueous ammonium
formate−acetonitrile, 40:60, UV detection at 254 nm). HRMS:
calculated for C25H25N2O (M+H) 369.1967; found 369.1961 (M +H).
4-{[(1E)-3-[2-(Morpholin-4-yl)ethyl]-1H-inden-1-ylidene]methyl}-
quinoline (2-5p). Yellow solid (25 mg, 5.8%). 1H NMR (300 MHz,
CDCl3) δ 2.55 (t, J = 4.4 Hz, 4H), 2.65−2.76 (m, 2H), 2.78−2.89 (m,
2H), 3.75 (t, J = 4.5 Hz, 4H), 6.54 (s, 1H), 7.27−7.40 (m, 3H), 7.47 (d, J
= 4.4 Hz, 1H), 7.55−7.64 (m, 1H), 7.70−7.82 (m, 2H), 7.85 (s, 1H),
8.02−8.22 (m, 2H) 8.97 (d, J = 4.4 Hz, 1H). 13C NMR (75.5 MHz,
CDCl3) δ 25.34, 53.66 (2C), 57.24, 66.92 (2C), 119.06, 119.61, 120.86,
122.04, 122.51, 124.60, 125.93, 126.86, 127.20, 128.40, 129.59, 130.14,
137.12, 142.63, 143.06, 143.91, 148.17, 148.51, 149.93. HPLC 95%
(Waters X-Bridge C-18 5 μm, 4.6 mm × 100 mm column, 10 mM
aqueous NH4OAc−CH3CN, 40:60, UV detection at 254 nm). HRMS:
calculated for C25H25N2O (M +H) 369.1967, found 369.1957 (M +H).
4-{2-[(1E)-1-(1,2-Dihydroacenaphthylen-5-ylmethylidene)-1H-
inden-3-yl]ethyl}morpholine (2-5q). Yellow solid (120 mg, 26%). 1H
NMR (300MHz, CDCl3) δ 2.52 (t, J = 4.5 Hz, 4H), 2.65−2.75 (m, 2H),
2.77−2.87 (m, 2H), 3.41 (s, 4H), 3.74 (t, J = 4.5 Hz, 4H), 6.73 (s, 1H),
7.23−7.38 (m, 5H), 7.46−7.54 (m, 1H), 7.66 (d, J = 7.2 Hz, 1H), 7.76−
7.86 (m, 2H), 7.96 (s, 1H). 13C NMR (75.5 MHz, CDCl3) δ 23.15,
28.04, 28.33, 51.49 (2C), 55.33, 64.81 (2C), 116.45, 116.53, 117.00,
117.52, 120.71, 121.61, 123.03, 125.06, 126.13, 127.82, 128.40, 128.53,
135.72, 137.16, 137.89, 139.83, 140.40, 143.46, 144.22, 144.64. HPLC
95% (Waters X-Bridge C-18 5 μm, 4.6 mm × 100 mm column, 10 mM
aqueous NH4OAc−CH3CN, 40:60, UV detection at 254 nm). HRMS:
calculated for C28H28NO (M + H) 394.2171, found 394.2172 (M + H).
4-{2-[(1E)-1-(Naphthalen-2-ylmethylidene)-1H-inden-3-yl]ethyl}-
morpholine (2-5r). Yellow film (172 mg, 38%). 1H NMR (300 MHz,
CDCl3) δ 2.57 (t, J = 4.4 Hz, 4H), 2.70−2.80 (m, 2H), 2.81−2.93 (m,
2H), 3.77 (t, J = 4.6 Hz, 4H), 6.94 (s, 1H), 7.22−7.36 (m, 3H), 7.47−
7.56 (m, 3H), 7.69−7.79 (m, 3H), 7.80−7.92 (m, 3H), 8.02 (s, 1H). 13C
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NMR (75.5 MHz, CDCl3) δ 23.35, 51.62 (2C), 55.46, 64.95 (2C),
116.63, 116.96, 120.02, 123.32, 124.39, 124.49, 124.55, 125.26, 125.29,
125.60, 126.14, 126.18, 127.76, 130.82, 131.38, 132.67, 136.19, 137.51,
140.05, 144.68. HPLC 99% (Waters X-Bridge C-18 5 μm, 4.6 mm× 100
mm column, 0.05% aqueous TFA−CH3CN, 40:60, UV detection at 254
nm). HRMS: calculated for C26H26NO (M + H) 368.2014, found
368.2011 (M + H).
4-{2-[(1E)-1-(Phenanthren-4-ylmethylidene)-1H-inden-3-yl]-
ethyl}morpholine (2-5s). Yellow solid (190 mg, 37%). 1H NMR (300
MHz, CDCl3) δ 2.51 (t, J = 4.4 Hz, 4H), 2.64−2.73 (m, 2H), 2.78−2.88
(m, 2H), 3.73 (t, J = 4.6 Hz, 4H), 6.66 (s, 1H), 7.27−7.38 (m, 3H),
7.59−7.74 (m, 4H), 7.81−7.87 (m, 2H), 7.91−7.96 (m, 1H), 7.98 (m,
3H), 8.12−8.19 (m, 1H), 8.66−8.78 (m, 2H). 13C NMR (75.5 MHz,
CDCl3) δ 25.41, 53.73 (2C), 57.45, 67.06 (2C), 118.83, 119.37, 122.67,
122.83, 123.13, 124.66, 125.47, 125.63, 126.85, 126.89, 126.98, 127.12,
127.71, 129.01, 130.05, 130.39, 130.44, 131.28, 131.57, 132.94, 137.51,
141.78, 143.13, 146.14. HPLC 99% (Waters X-Bridge C-18 5 μm, 4.6
mm × 100 mm column, 0.05% aqueous TFA−CH3CN, 40:60, UV
detection at 254 nm). HRMS: calculated for C30H28NO (M + H)
418.2171, found 418.2174 (M + H).
4-{2-[(1E)-1-[(4-Ethylnaphthalen-1-yl)methylidene]-1H-indenyl]-
ethyl}morpholine (2-5t). Yellow film (290 mg, 62%). 1H NMR (300
MHz, CDCl3) δ 1.40 (t, J = 7.6 Hz, 3H), 2.48 (t, J = 4.4 Hz, 4H), 2.60−
2.70 (m, 2H), 2.73−2.85 (m, 2H), 3.12 (q, J = 7.5 Hz, 2H), 3.71 (t, J =
4.5 Hz, 4H), 6.63 (s, 1H), 7.22−7.34 (m, 3H), 7.38 (d, J = 7.4 Hz, 1H),
7.46−7.58 (m, 3H), 7.74−7.81 (m, 1H), 7.98 (s, 1H), 8.04−8.18 (m,
2H). 13C NMR (75.5 MHz, CDCl3) δ 15.08, 25.44, 26.14, 53.78 (2C),
57.58, 67.09 (2C), 118.79, 119.33, 123.02, 124.38, 124.68, 124.86,
125.41, 125.54, 126.03 (2C), 127.55, 129.19, 131.97, 132.55, 132.60,
137.77, 140.95, 141.18, 142.94, 145.89. HPLC 97% (Waters X-Bridge
C-18 5 μm, 4.6 mm × 100 mm column, 10 mM aqueous NH4OAc−
CH3CN, 40:60, UV detection at 254 nm). HRMS: calculated for
C28H30NO (M + H) 396.2327, found 396.2332 (M + H).
4-{2-[(1E)-1-[(4-Propylnaphthalen-1-yl)methylidene]-1H-inden-3-
yl]ethyl}morpholine (2-5u). Yellow solid (135 mg, 96% pure by HPLC,
29%; scale up 913 mg, 62%). 1H NMR (300 MHz, CDCl3) δ 1.07 (t, J =
7.3 Hz, 3H), 1.74−1.90 (m, 2H), 2.53 (t, J = 4.5 Hz, 4H), 2.63−2.76 (m,
2H), 2.77−2.89 (m, 2H), 3.09 (q, J = 7.5 Hz, 2H), 3.74 (t, J = 4.6 Hz,
4H), 6.65 (s, 1H), 7.25−7.36 (m, 3H), 7.39 (d, J = 7.3 Hz, 1H), 7.48−
7.60 (m, 3H), 7.77−7.84 (m, 1H), 8.00 (s, 1H), 8.07−8.19 (m, 2H). 13C
NMR (75.5 MHz, CDCl3) δ 14.36, 23.97, 25.40, 35.38, 53.75 (2C),
57.55, 67.07 (2C), 118.73, 119.24, 123.00, 124.53, 124.83, 125.33,
125.46, 125.70, 125.90, 125.93, 127.48, 128.96, 132.08, 132.52, 132.60,
137.71, 139.67, 140.86, 142.89, 145.82. HPLC (Waters X-Bridge C-18 5
μm, 4.6 mm × 100 mm column, 10 mM aqueous ammonium formate−
acetonitrile, 40:60, UV detection at 254 nm). HRMS: calculated for
C29H32NO (M + H) 410.2484, found 410.2474 (M + H).
CB1/CB2R Binding Assays. Detailed radioligand displacement
assays (using the well-characterized CBR agonist (−)-cis-3-[2-hydroxy-
4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol
[2,3,4-3H] [3H]-CP55940 as the radioligand)42 were conducted to
determine the affinity (Ki) of the test compounds for CB1R and CB2R
as has been previously described by our group.27,43 Heterologous
competition binding assays were performed to calculate receptor
affinities. Unlabeled 226 or 3 were used as appropriate controls for
nonspecific binding in the assay. Calculation of the equilibrium
dissociation constant (Ki) was performed using the Cheng−Prusoff
equation.
Calcium Flux Assay. Chinese hamster ovary cells stably expressing
either human CB1 or CB2 cDNA and the promiscuous G-protein Gαq16
were removed from their flasks using the nonenzymatic cell-stripper
(Mediatech Inc.) and quenched with DMEM/F12, 10% FBS,
centrifuged, and resuspended in the serum-containing media. Cells
were counted with a hemocytometer and 40000 cells were transferred to
each well of a black Costar 96-well optical bottom plate (Corning
Corporation). Each plate was incubated at 37 °C for 24 h to confluence.
The culture media were removed from the plates, and cells were
subsequently loaded with a fluorescent calcium probe (Fluo-4 AM dye,
Invitrogen/Molecular Probes) at a final loading concentration of 2 μM
in a HBSS-based buffer containing 20 mMHEPES, 1% BSA, and 10 μM
Probenecid (Sigma) in a total volume of 225 μL. Cells were incubated at
37 °C for 1 h and then stimulated with various concentrations of a test
agent using a FlexStation plate-reader, which automatically added the
agonist at 10× concentration to each well after reading baseline values
for ∼17 s. Agonist-mediated change in fluorescence (488 nm excitation,
525 nm emission) was monitored in each well at 1 s intervals for 60 s and
reported for each well. Data were collected using Softmax version 4.8
(MDS Analytical Technologies) and analyzed using Prism software
(GraphPad). Nonlinear regression analysis was performed to fit data and
obtain maximum response (Emax), effective concentration for 50%
response (EC50), correlation coefficient (r
2), and other parameters. All
experiments were performed 3−6 times to ensure reproducibility and
data reported as mean ± standard error of the mean unless noted
otherwise.
MDCK-mdr1 Permeability Assays. MDCK-mdr1 cells obtained
from The Netherlands Cancer Institute were grown on Transwell type
filters (Corning) for 4 days to confluence in DMEM/F12 media
containing 10% fetal bovine serum and antibiotics as has been described
previously.43 Compounds were added to the apical side at a
concentration of 10 μM in a transport buffer comprising of Hank’s
balanced salt solution, 25 mM D-glucose and buffered with HEPES to
pH 7.4. Samples were incubated for 1 h at 37 °C and carefully collected
from both the apical and basal side of the filters. Compounds selected for
MDCK-mdr1 cell assays were infused on an Applied Biosystems API-
4000 mass spectrometer to optimize for analysis using multiple reaction
monitoring (MRM). Flow injection analysis was also conducted to
optimize for mass spectrometer parameters. Samples from the apical and
basolateral side of the MDCK cell assay were dried under nitrogen on a
Turbovap LV. The chromatography was conducted with an Agilent
1100 binary pumpwith a flow rate of 0.5 mL/min.Mobile phase solvents
were A, 0.1% formic acid in water, and B, 0.1% formic acid in methanol.
The initial solvent conditions were 10% B for 1 min, then a gradient was
used by increasing to 95% B over 5 min, then returning to initial
conditions. Data reported are average values from 2 to 3 measurements.
Plasma Stability Assay. Compounds were incubated at 10 μM in
rat plasma at 37 °C. A solution of each compound was prepared in
ethanol at a concentration of 1 mM. A 2.5 μL volume of the 1 mM
solution was added to 247.5 μL of rat plasma (adult male Sprague−
Dawley) in a glass test tube in a 37 °Cwater bath. Samples (50 μL) were
removed at 0, 30, and 60 min and immediately extracted with 3 volumes
(150 μL) of methanol. Samples were centrifuged (2500 rpm for 10 min
at 4 °C) to pellet protein and supernatants transferred to LC/MS vials
for analysis. Samples were stored at −80 °C prior to analysis.
S9 Fraction Stability Assay.Compounds were incubated at 10 μM
in rat (male Sprague−Dawley) liver S9 fraction at 37 °C. Each
compound was prepared in ethanol at a concentration of 1mM. An assay
mixture containing S9 (1 mg protein/mL final concentration) and an
NADPH regenerating system (NADP [1 mM final], glucose 6-
phosphate [5 mM final], and glucose 6-phosphate dehydrogenase [1
U/mL final]) in a buffer consisting of 50 mM KPO4 phosphate buffer,
pH 7.4, with 3 mMMgCl2 was prepared and preincubated at 37 °C for 5
min. A 10 μL volume of the 1 mM solution was added to 990 μL of assay
mixture in a glass test tube at 37 °C to initiate the assay. Samples (50 μL)
were removed at 0, 15, 30, 60, and 120 min and immediately extracted
with 3 volumes (150 μL) of methanol, centrifuged to pellet protein, and
supernatants transferred to LC/MS vials for analysis.
Animals. The Institutional Animal Care and Use Committee
approved all animal experiments. Sprague−Dawley male rats (Harlan
Laboratories) weighing 200−220 g at arrival were maintained on a 12 h
light/dark cycle with free access to food and water at the UCLADivision
of Laboratory of Animal Medicine facilities.
Behavioral Testing. Naıv̈e rats were tested for CNS side effects
before and after drug administration in the “tetrad” of tests that are
classically predictive of cannabinoid receptor activation.24 Rats were also
tested for behavioral responses to tactile stimuli before and after sciatic
nerve entrapment neuropathy induction. The methods for generation of
this model were exactly as previously described.44 Analgesic
effectiveness of PRCBs was tested at 3-day intervals beginning 8 days
after SNE surgery. Each behavioral test is described briefly below.
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Rotarod. Rats were tested for motor function and the ataxic effects of
drugs as described previously.4b,45 Rats were trained 72 h before the test
(3 sessions 24 h apart) to remain for at least 180 s on a rotarod revolving
at an acceleration of 4−40 revs over 5 min). Rats were tested 1 h before
vehicle or drug injections and tested again at 2, 6, 24, and 48 h after drug
or vehicle administration. The time for which the rats are able to remain
on the rotarod was recorded up to a cutoff of 3 min.
Hypothermia. Rats were acclimated to a plastic restrainer apparatus
(Model RTV-180 Braintree Scientific Inc.) on the day of testing by
placing them in the restrainer twice for 5 min separated by 20 min.
Baseline core temperature was taken before treatment, and again at 2, 6,
and 24 and 48 h after drug/vehicle injection.
Catalepsy (Ring) Test. Catalepsy was determined with a ring
immobility test,46 modified for rats.4b,24a Rats were placed with their
forepaws on a horizontal metal ring (12 cm diameter) at a height that
allowed their hindpaws to just touch the bench surface. Immobility was
recorded as the time for the rat to move off the ring with a 100 s cutoff.
Rats were tested before vehicle/drug injections and again at 2, 6, 24, and
48 h after injection.
Tail-Flick Test. A modified Hargreaves apparatus (model 390, IITC
Instr.) was also used to measure tail-flick latency (TFL). Radiant heat
was directed to a point 3 cm from the tail tip and the TFL observed and
timed with a photo cell counter. The intensity of the radiant heat was
adjusted for a baseline TFL of approximately 5−7 s for naıv̈e rats, with a
25 s cutoff set to avoid tissue damage.
Mechanical Sensitivity. Rats were placed in a plastic-walled cage (10
× 20 × 13 cm3) with a metal mesh floor (0.6 × 0.6 cm2 holes) and
allowed to acclimate for 10 min. The amount of pressure (g) needed to
evoke a hindpaw withdrawal response was measured 4 times on each
paw separated by 30-s intervals using a von Frey-type digital meter
(model 1601C, IITC Instr.). Results of 4 tests/session were averaged for
each paw.
Drug Administration. For intraperitoneal (ip) injection, drugs were
first dissolved in a 50/50% mixture of pure DMSO and Cremophor EL
(Sigma-Aldrich), then appropriately diluted in sterile saline (1.5 mL/kg
for ip) and administered using 271/2 gauge sterile needles and 1 cm3
syringes equipped with a 0.22 μm filter. For oral administration, drugs
were dissolved in pure DMSO, appropriately diluted in 20% sweet
condensed milk (16 mL/kg), and delivered directly in the stomach by
oral intubation with the aid of a ball-tipped gavage needle and a 5 cc
syringe.
Body Fluid and Tissue Collection for Pharmacokinetics Assays. (A)
Plasma collection: rats were administered CB1R ligands and blood
samples (∼110 μL) collected from the tail vein at various intervals after
brief (<5 min) placement in a plastic restraining apparatus (RTV-180,
Braintree Scientific Inc., Braintree, MA). Samples were centrifuged at
12000 rpm for 3 min and the plasma supernatant (∼50 μL) placed in
heparinized capillary tubes and stored at −20 °C until analysis. (B) CSF
collection: rats were anesthetized (isoflurane) placed in a stereotactic
frame, the dura exposed at the level of the cisterna magna, 100−150 μL
of CSF collected as per,47 and stored at −20 °C until analysis. (C) Brain
collection: rats were terminally anesthetized (pentobarbital, 75 mg/kg),
perfused intracardially with 60 mL of cold saline, and the brain rapidly
removed and stored at −20 °C until analysis.
Mass Spectroscopy Analysis of Fluid and Tissue Samples. Plasma,
CSF, and brain samples were analyzed by LC-MS/MS and quantified
using standard curves prepared from appropriate drug dilutions in
samples obtained from untreated animals.48
Statistical Analysis. The investigator performing all of the
behavioral tests was blind to the dose and nature of drugs administered
to the rats. One-way or two-way repeated measurements analysis of
variance (RM ANOVA) were used to assess significance of drug effects.
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